0001698530-24-000068.txt : 20240617 0001698530-24-000068.hdr.sgml : 20240617 20240617162700 ACCESSION NUMBER: 0001698530-24-000068 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240617 DATE AS OF CHANGE: 20240617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXICURE, INC. CENTRAL INDEX KEY: 0001698530 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 815333008 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39011 FILM NUMBER: 241048637 BUSINESS ADDRESS: STREET 1: 2430 N. HALSTED ST. CITY: CHICAGO STATE: IL ZIP: 60614 BUSINESS PHONE: 847-673-1700 MAIL ADDRESS: STREET 1: 2430 N. HALSTED ST. CITY: CHICAGO STATE: IL ZIP: 60614 FORMER COMPANY: FORMER CONFORMED NAME: Max-1 Acquisition Corp DATE OF NAME CHANGE: 20170221 10-Q 1 xcur-20240331.htm 10-Q xcur-20240331
000169853012/312024Q1false.0208.0208.0278.0833xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesutr:sqftxcur:extension_periodxbrli:purexcur:agreementxcur:vote00016985302024-01-012024-03-3100016985302024-06-1000016985302024-03-3100016985302023-12-3100016985302023-01-012023-03-310001698530us-gaap:CommonStockMember2023-12-310001698530us-gaap:AdditionalPaidInCapitalMember2023-12-310001698530us-gaap:RetainedEarningsMember2023-12-310001698530us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001698530us-gaap:CommonStockMember2024-01-012024-03-310001698530us-gaap:RetainedEarningsMember2024-01-012024-03-310001698530us-gaap:CommonStockMember2024-03-310001698530us-gaap:AdditionalPaidInCapitalMember2024-03-310001698530us-gaap:RetainedEarningsMember2024-03-310001698530us-gaap:CommonStockMember2022-12-310001698530us-gaap:AdditionalPaidInCapitalMember2022-12-310001698530us-gaap:RetainedEarningsMember2022-12-3100016985302022-12-310001698530us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001698530us-gaap:CommonStockMember2023-01-012023-03-310001698530us-gaap:RetainedEarningsMember2023-01-012023-03-310001698530us-gaap:CommonStockMember2023-03-310001698530us-gaap:AdditionalPaidInCapitalMember2023-03-310001698530us-gaap:RetainedEarningsMember2023-03-3100016985302023-03-310001698530us-gaap:EquipmentMember2024-03-310001698530us-gaap:EquipmentMember2023-12-310001698530xcur:ComputersandSoftwareMember2024-03-310001698530xcur:ComputersandSoftwareMember2023-12-310001698530us-gaap:FurnitureAndFixturesMember2024-03-310001698530us-gaap:FurnitureAndFixturesMember2023-12-310001698530xcur:ChicagoMember2020-07-012020-07-010001698530xcur:ChicagoMember2020-07-010001698530xcur:ChicagoMember2023-05-042023-05-040001698530us-gaap:NotesReceivableMember2023-05-012023-05-310001698530xcur:NotesReceivableTwoMember2023-05-310001698530xcur:NotesReceivableOneMember2023-05-310001698530us-gaap:NotesReceivableMember2023-05-310001698530us-gaap:NotesReceivableMember2024-03-012024-03-310001698530us-gaap:PrivatePlacementMember2022-09-262022-09-260001698530us-gaap:PrivatePlacementMember2022-09-260001698530us-gaap:PrivatePlacementMember2023-02-242023-02-240001698530xcur:ThirdPartySaleOfCompanyStockMemberxcur:CBIUSAIncMemberxcur:DGPCoLtdMember2023-06-232023-06-230001698530xcur:ThirdPartyMemberxcur:ThirdPartySaleOfCompanyStockMemberxcur:DGPCoLtdMember2024-02-290001698530xcur:ThirdPartyMemberxcur:ThirdPartySaleOfCompanyStockMemberxcur:DGPCoLtdMember2024-02-012024-02-290001698530xcur:CBIUSADGPCoLtdMemberus-gaap:PrivatePlacementMember2024-01-012024-03-3100016985302022-09-262022-09-260001698530xcur:CBIUSAIncMember2024-01-012024-03-310001698530xcur:DGPCoLtdMember2024-03-310001698530us-gaap:CommonStockMember2021-12-162021-12-160001698530us-gaap:CommonStockMember2021-12-160001698530xcur:PreFundedWarrantsMember2021-12-162021-12-160001698530us-gaap:WarrantMember2021-12-162021-12-160001698530xcur:CommonStockAndAccompanyingWarrantMember2021-12-162021-12-160001698530xcur:PreFundedWarrantsAndAccompanyingWarrantMember2021-12-162021-12-160001698530xcur:PreFundedWarrantsMember2021-12-160001698530us-gaap:WarrantMember2021-12-1600016985302021-12-1600016985302021-12-162021-12-1600016985302021-12-3100016985302023-06-232023-06-230001698530xcur:ExicureInc.2017EquityIncentivePlanMember2017-09-220001698530xcur:ExicureOpCo2015EquityIncentivePlanMember2017-09-220001698530xcur:ExicureInc.2017EquityIncentivePlanMember2024-01-012024-03-310001698530xcur:ExicureInc.2017EquityIncentivePlanMember2024-03-310001698530xcur:ExicureInc.2017EquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2023-01-010001698530us-gaap:ShareBasedCompensationAwardTrancheOneMemberxcur:ExicureInc.2017EquityIncentivePlanMemberxcur:InitialEmployeeStockOptionMember2024-01-012024-03-310001698530xcur:ExicureInc.2017EquityIncentivePlanMemberxcur:InitialEmployeeStockOptionMember2024-01-012024-03-310001698530xcur:SubsequentEmployeeStockOptionMemberxcur:ExicureInc.2017EquityIncentivePlanMember2024-01-012024-03-310001698530xcur:ExicureInc.2017EquityIncentivePlanMemberxcur:NonemployeeDirectorMemberxcur:InitialEmployeeStockOptionMember2024-01-012024-03-310001698530xcur:SubsequentEmployeeStockOptionMemberxcur:ExicureInc.2017EquityIncentivePlanMemberxcur:NonemployeeDirectorMember2024-01-012024-03-310001698530xcur:ExicureInc.2017EquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2024-01-012024-03-310001698530us-gaap:EmployeeStockMember2017-09-300001698530us-gaap:EmployeeStockMember2017-09-012017-09-300001698530us-gaap:EmployeeStockMember2023-01-012023-01-010001698530us-gaap:EmployeeStockMember2024-03-310001698530us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001698530us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001698530us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001698530us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001698530srt:MinimumMember2023-01-012023-03-310001698530srt:MaximumMember2023-01-012023-03-310001698530srt:WeightedAverageMember2023-01-012023-03-310001698530srt:WeightedAverageMember2023-03-3100016985302023-01-012023-12-310001698530us-gaap:RestrictedStockUnitsRSUMember2023-12-310001698530us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001698530us-gaap:RestrictedStockUnitsRSUMember2024-03-310001698530us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001698530us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001698530us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001698530us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001698530xcur:PerformanceBasedRestrictedStockMember2024-01-012024-03-310001698530xcur:PerformanceBasedRestrictedStockMember2023-01-012023-03-310001698530us-gaap:WarrantMember2024-01-012024-03-310001698530us-gaap:WarrantMember2023-01-012023-03-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001698530us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-03-310001698530us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001698530us-gaap:NotesReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001698530us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001698530us-gaap:NotesReceivableMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001698530us-gaap:FairValueInputsLevel3Memberus-gaap:NotesReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001698530us-gaap:FairValueMeasurementsRecurringMember2024-03-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001698530us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001698530us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001698530us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001698530us-gaap:NotesReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001698530us-gaap:NotesReceivableMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001698530us-gaap:NotesReceivableMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001698530us-gaap:FairValueInputsLevel3Memberus-gaap:NotesReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001698530us-gaap:FairValueMeasurementsRecurringMember2023-12-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001698530us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001698530us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001698530us-gaap:RelatedPartyMember2023-02-272023-02-270001698530xcur:BiopharmaceuticalCompanyMember2024-02-052024-02-050001698530us-gaap:SubsequentEventMemberxcur:PromissoryNoteMember2024-05-030001698530us-gaap:SubsequentEventMemberxcur:PromissoryNoteMemberus-gaap:RelatedPartyMemberxcur:DGPCoLtdMember2024-06-030001698530us-gaap:SubsequentEventMemberxcur:PromissoryNoteMemberus-gaap:RelatedPartyMemberxcur:DGPCoLtdMember2024-06-032024-06-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________
FORM 10-Q
______________________________________
☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
or
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission File Number: 001-39011
______________________________________
EXICURE, INC.
(Exact name of registrant as specified in its charter)
_____________________________________
Delaware
81-5333008
(State or other jurisdiction of
incorporation or organization)
(IRS Employer
Identification No.)
2430 N. Halsted St.
Chicago, IL 60614
(Address of principal executive offices)

Registrant’s telephone number, including area code (847) 673-1700
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareXCURThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).     Yes  ☐   No  ☒
As of June 10, 2024, there were 8,651,148 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.


EXICURE, INC.
QUARTERLY REPORT ON FORM 10-Q
TABLE OF CONTENTS


2
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, including the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains express or implied “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”). All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,”, “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “project,” “continue,” “potential,” “ongoing” or the negative of these terms or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements.
Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part II, Item 1A “Risk Factors” below and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law. These forward-looking statements include, but are not limited to, statements concerning the following:
•substantial uncertainties regarding our exploration of strategic alternatives to maximize stockholder value, including whether we are able to identify potential partners and consummate transactions, in a timely manner or at all, whether we would be able to obtain sufficient funding to complete this process and whether any such transactions would generate value for stockholders;
•our ability to generate any meaningful value from sales, out-licensing or other transactions involving our historical assets;
•our ability to raise the substantial additional capital that is needed in the very near term to fund our operations and our pursuit of strategic alternatives, particularly given our current lack of a revenue source or committed financing and the substantial doubt about our ability to continue as a going concern;
•our ability to successfully appeal the delisting determination made by the Nasdaq staff and correct deficiencies and to remain listed on The Nasdaq Capital Market (“Nasdaq”), including the ability to maintain minimum stockholders’ equity and stock price, and comply with applicable governance requirements, among other requirements, for continued listing on Nasdaq;

•any strategic plan or alternative that we may identify and pursue may involve unexpected costs, liabilities and/or delays and may not deliver anticipated benefits to our stockholders;
•our estimates of expenses, use of cash, timing of future cash needs, ongoing losses and capital requirements may prove to be inaccurate;
•uncertainty about reaction from investors and potential business partners to our recent changes of control and board and management composition and the future direction of the Company, and the ability of our controlling stockholders and new board members and management to earn the confidence of investors and potential partners despite limited experience with U.S. public companies, and how these factors may impact our ability to obtain funding and execute any strategic alternatives that we may identify;
•potential additional turnover of senior management, and any inability to attract and retain qualified management and other key personnel, creates significant continuity risk and could impair our ability to raise capital and execute on our exploration of strategic alternatives;
3
•our ability to comply with all applicable laws, which may be particularly challenging given the recent turnover in our board and management, significant reductions in force, limited resources and the potential to enter into new business areas with which we have no past experience;
•our ability to obtain and maintain intellectual property protection for our technologies and our ability to operate our business without infringing the intellectual property rights of others;
•the impact of macroeconomic conditions, including global inflation, actions taken by central banks to counter inflation, capital market and bank instability, exchange rate fluctuations, supply chain disruptions and energy and fuel prices;
•the impact of government laws and regulations; and
•other factors that may impact our financial results and condition and our ongoing strategic efforts.
These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in Part II, Item 1A of this Quarterly Report on Form 10-Q under the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.
Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed with the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no, and specifically decline any, obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
This Quarterly Report on Form 10-Q also contains or may contain estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.
Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the “Company,” “Exicure,” “we,” “us” and “our” refers to Exicure, Inc., a Delaware corporation, and, where appropriate, our subsidiary.


4
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
March 31,
2024		December 31,
2023
ASSETS
Current assets:
Cash and cash equivalents$366 $816 
Other receivable1 15 
Prepaid expenses and other current assets1,096 1,193 
Total current assets1,463 2,024 
Property and equipment, net47 54 
Right-of-use asset6,323 6,517 
Other noncurrent assets2,878 2,985 
Total assets$10,711 $11,580 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable1,825 1,631 
Accrued expenses and other current liabilities836 879 
Total current liabilities2,661 2,510 
Lease liability, noncurrent5,843 6,039 
Total liabilities8,504 8,549 
Commitments and Contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, March 31, 2024 and December 31, 2023
— — 
Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 8,650,950 issued and outstanding, March 31, 2024; 8,650,753 issued and outstanding, December 31, 2023
1 1 
Additional paid-in capital192,598 192,593 
Accumulated deficit(190,392)(189,563)
Total stockholders’ equity2,207 3,031 
Total liabilities and stockholders’ equity$10,711 $11,580 
See accompanying notes to the unaudited condensed consolidated financial statements.

5
EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)

Three Months Ended
March 31,
20242023
Revenue:
     Revenue$500 $— 
          Total revenue500 — 
Operating expenses:
     Research and development expense— 1,423 
     General and administrative expense1,336 3,116 
          Total operating expenses1,336 4,539 
Operating loss(836)(4,539)
Other income, net:
     Dividend income4 17 
     Interest income3 11 
     Other income, net— 104 
          Total other income, net7 132 
Net loss before provision for income taxes(829)(4,407)
Provision for income taxes— — 
Net loss$(829)$(4,407)
Basic and diluted loss per common share$(0.10)$(0.70)
Weighted-average basic and diluted common shares outstanding8,650,878 6,288,952 
See accompanying notes to the unaudited condensed consolidated financial statements.

6
EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except shares)

Common Stock
Shares$Additional Paid-in- CapitalAccumulated DeficitTotal Stockholders' Equity
Balance at January 1, 20248,650,753 $1 $192,593 $(189,563)$3,031 
Equity-based compensation— — 5 — 5 
Vesting of restricted stock units and related repurchases197 — — — — 
Net loss— — — (829)(829)
Balance at March 31, 20248,650,950 $1 $192,598 $(190,392)$2,207 
See accompanying notes to the unaudited condensed consolidated financial statements.
7
EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except shares)

Common Stock
Shares$Additional Paid-in- CapitalAccumulated DeficitTotal Stockholders' Equity
Balance at January 1, 20234,965,901 $— $187,571 $(172,649)$14,922 
Equity-based compensation — — 308 — 308 
Reclassification of common stock warrants to liability— — (800)— (800)
Vesting of restricted stock units and related repurchases5,561 1 (2)— (1)
Issuance of common stock, net3,400,000 — 4,597 — 4,597 
Net loss— — — (4,407)(4,407)
Balance at March 31, 20238,371,462 $1 $191,674 $(177,056)$14,619 
See accompanying notes to the unaudited condensed consolidated financial statements.
8
EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Three Months Ended March 31,
20242023
Cash flows from operating activities:
Net loss$(829)$(4,407)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization7 251 
Equity-based compensation5 308 
Amortization of right-of-use asset194 180 
Other— (105)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets218 157 
Other noncurrent assets— 180 
Accounts payable194 91 
Accrued expenses(43)199 
Other liabilities(196)(172)
Net cash used in operating activities(450)(3,318)
Cash flows from investing activities:
Proceeds from sale of property and equipment— 106 
Net cash provided by investing activities— 106 
Cash flows from financing activities:
Proceeds from common stock offering— 5,440 
Payment of common stock financing costs— (843)
Payments for minimum statutory tax withholding related to net share settlement of equity awards— (2)
Net cash provided by provided by financing activities— 4,595 
Net (decrease) increase in cash, cash equivalents, and restricted cash(450)1,383 
Cash, cash equivalents, and restricted cash - beginning of period2,016 9,777 
Cash, cash equivalents, and restricted cash - end of period$1,566 $11,160 

See accompanying notes to the unaudited condensed consolidated financial statements.

9

EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
(in thousands)


Three Months Ended March 31,
20242023
Supplemental disclosure of cash flow information
Non-cash investing activities:
Reclassification of common stock warrants to liability$— $800 
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the amounts shown in the unaudited condensed consolidated statements of cash flows:
March 31,
2024		December 31,
2023
Cash and cash equivalents$366 $816 
Restricted cash included in other noncurrent assets1,200 1,200 
Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows$1,566 $2,016 

See accompanying notes to the unaudited condensed consolidated financial statements.

10
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)



1. Description of Business, Basis of Presentation and Going Concern
Description of Business
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. While the foregoing efforts are continuing with respect to the Company’s historical assets, the Company does not expect they will generate significant value for stockholders. Therefore, the Company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. The Company is exploring transactions in industries unrelated to its historical operations.
Throughout these unaudited condensed consolidated financial statements, the terms the “Company,” and “Exicure” refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company. Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc. 
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023, and for the three months ended March 31, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.
Unaudited Interim Financial Information
The accompanying interim condensed consolidated balance sheet as of March 31, 2024, the interim condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the interim condensed consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2024 and 2023, and the interim condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023, and the results of its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, or any other interim periods, or any future year or period. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on June 6, 2024.

11
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


Going Concern
At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.
The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the financial statements are issued. As of March 31, 2024, the Company expects to incur significant expenses and negative cash flows for the foreseeable future. As of March 31, 2024, the Company’s cash and cash equivalents were $366. Management believes that, given the Company’s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. Substantial additional financing will be needed by the Company to fund its operations.
Management believes that the Company’s existing cash and cash equivalents are insufficient to continue to fund its operating expenses and additional funding is needed in the very near term. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend the Company’s operating runway is limited. As a result, substantial additional financing will be needed by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.
The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
2. Significant Accounting Policies
The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company’s Annual Report on Form 10-K (the “Annual Report”) for the year ended December 31, 2023 filed with the SEC on June 6, 2024. Since the date of those audited consolidated financial statements, there have been no material changes to the Company’s significant accounting policies.
Use of Estimates
The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.



12
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


3. Supplemental Balance Sheet Information
Prepaid expenses and other current assets
March 31, 2024December 31, 2023
Prepaid insurance$480 $508 
Prepaid franchise tax160 259 
Lease costs250 235 
Prepaid professional fees70 95 
Prepaid software 63 72 
Other73 24 
     Prepaid expenses and other current assets$1,096 $1,193 
Other noncurrent assets
March 31, 2024December 31, 2023
Restricted cash$1,200 $1,200 
Prepaid insurance1,678 1,785 
     Other noncurrent assets$2,878 $2,985 
Property and equipment, net
March 31, 2024December 31, 2023
Scientific equipment$246 $246 
Computers and software3 3 
Furniture and fixtures30 30 
Property and equipment, gross279 279 
Less: accumulated depreciation and amortization(232)(225)
Property and equipment, net$47 $54 
Depreciation and amortization expense was $7 and $251 for the three months ended March 31, 2024 and 2023, respectively.
Accrued expenses and other current liabilities
March 31, 2024December 31, 2023
Lease liability$650 $626 
Accrued payroll-related expenses43 71 
Accrued other expenses143 182 
     Accrued expenses and other current liabilities$836 $879 
4. Leases
The Company’s lease arrangements at March 31, 2024 consist of (i) a lease for office space at its headquarters in Chicago, Illinois that commenced in July 2020 (the “Chicago Lease”) and (ii) a lease for office equipment (the “Office Equipment Lease”). The Chicago Lease and the Office Equipment Lease are classified as operating leases.
13
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


Chicago Lease
The Company has approximately thirty thousand square feet of office space in Chicago, Illinois. The original term (the “Original Term”) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the “Commencement Date”), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the “Extension Periods”) at the then prevailing effective market rental rate.
The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes were subject to certain abatements.
The following table summarizes lease costs in the Company’s unaudited condensed consolidated statement of operations:
Three Months Ended
March 31,
20242023
Operating lease costs$143 $326 
Variable lease costs120 332 
Short term lease costs11 — 
Total lease costs$274 $658 
The Company made cash payments for operating leases $0 and $646 during the three months ended March 31, 2024 and 2023, respectively. Amounts owed are included in accounts payable as of March 31, 2024. On June 11, 2024, the Company received a formal notice from its landlord indicating the landlord will draw on the restricted cash account designated for the lease as a result of past due rent for December 2023 through June 2024. This draw is within the terms and conditions of the lease and the related restricted cash account.
Sublease of Office Space
The Company entered into a sublease agreement with Cyclopure, Inc. (the “Subtenant”) to sublease approximately 57% of its office space pursuant to that certain sublease agreement (the “Sublease Agreement”), dated as of May 4, 2023. The term of the Sublease Agreement began on May 15, 2023 and ends on June 30, 2030, the expiration date of the Chicago Lease. The first three months under the Sublease Agreement are rent free. Beginning August 15, 2023, the Company began charging the Subtenant for 57% of the base rent under the Chicago Lease, and the subtenant is responsible for its pro rata share of operating expenses and taxes payable. In 2024, the Company does not receive payment from the Subtenant as the Subtenant pays the Company’s landlord directly.
The following table summarizes sublease receipts in the Company’s condensed consolidated statement of operations:
Three Months Ended
March 31,
20242023
Sublease amounts paid to landlord$173 $— 
Total$173 $— 
14
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


5. Investment in Convertible Notes Receivable
In May 2023, the Company entered into two subscription agreements to purchase non-guaranteed private placement convertible notes receivable (the “Notes Receivable”) for a subscription amount of $1 million each. The Notes Receivable mature in May 2026 and the yield to maturity is 4.5% per annum. The Company has the option to request that the issuer redeem part or the entire principal amount of the Notes Receivable on the first anniversary after the issue date and every three months thereafter before the maturity date. The conversion ratio will be one hundred percent (100%) of the Notes Receivable’s face value. The Company also has the ability to convert the debt into shares based on the number of shares computed by dividing the face value of each security by a calculated conversion price, which is subject to adjustment provisions, determined at the time of issuance. The securities may be converted from May 3, 2024, the first anniversary of the issue date of the first agreement, to April 15, 2026, one month prior to the maturity date to the second agreement. In March 2024, the Company notified the issuer of the Notes Receivable that it was exercising its redemption right with respect to the entire principal amount of the Notes Receivable after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of $2.090 million (representing the principal amount plus 4.5% per annum yield to the redemption date). The issuer has taken the position that the Notes Receivable are not redeemable until August 3, 2024 and August 16, 2024.
The Company’s debt securities are classified as AFS pursuant to Accounting Standards Codification (“ASC”) 320 - Investments - Debt Securities. AFS securities are recorded at fair value. As of March 31, 2024 and December 31, 2023, management does not believe these AFS investments are recoverable and recorded them at a fair value of $0.
6. Stockholders’ Equity
Preferred Stock
As of March 31, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.
Common Stock
As of March 31, 2024 and December 31, 2023, the Company had authorized 200,000,000 shares of common stock, par value $0.0001. As of March 31, 2024 and December 31, 2023, the Company had 8,650,950 shares and 8,650,753 shares issued and outstanding, respectively.
The holders of shares of the Company’s common stock are entitled to one vote per share on all matters to be voted upon by the Company’s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company’s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board of Directors (the “Board”) out of funds legally available for that purpose. In the event of the Company’s liquidation, dissolution or winding up, the holders of shares of the Company’s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company’s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company’s common stock. The outstanding shares of the Company’s common stock are fully paid and non-assessable.
15
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


September 2022 PIPE (Private Investment in Public Equity)
Securities Purchase Agreement
On September 26, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with CBI USA, Inc. (“CBI USA”), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of $1.60 per share. The private placement closed on February 24, 2023 (the “Closing Date”). The Company received gross proceeds of $5,440 from the September 2022 PIPE (or net proceeds of $4,597 after transaction expenses).
CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. (“DGP”). On June 23, 2023, DGP exercised its the option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on June 30, 2024.
The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any “group” of which it or they are a member with the right to designate directors to the Company’s board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on June 30, 2024.
September 2022 Registration Rights Agreement
In connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement with CBI USA (the “Registration Rights Agreement’). CBI USA assigned its rights under the Registration Rights Agreement to DGP when DGP acquired the 3,400,000 shares of Common Stock initially sold to CBI USA. Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the shares of Common Stock sold pursuant to the Securities Purchase Agreement, to use reasonable best efforts to cause such registration statement to become effective as promptly as practicable, and to keep such registration statement continuously effective until the earlier of (i) the date the shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction, or (ii) the date that is two (2) years following the Closing Date.
In the event the registration statement was not filed within 90 days following the Closing Date, subject to certain limited exceptions, the Company agreed to make payments as liquidated damages in an amount equal to 0.5% of the aggregate amount invested in the shares of Common Stock pursuant to the Securities Purchase Agreement per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. We have paid $27 to CBI USA and accrued $191 to DGP pursuant to this provision.

16
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


Registered Direct Offering
On December 16, 2021, the Company completed a securities purchase agreement (the “Purchase Agreement”) with certain institutional purchasers (the “Purchasers”) entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at-the-market consistent with the rules of Nasdaq (the “Registered Direct Offering”), (i) an aggregate of 433,553 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 718,981 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 576,261 shares of Common Stock (the “Warrants”). The combined purchase price of each share of Common Stock and accompanying Warrant is $9.9780 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is $9.9480 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.03). The per share exercise price for the Warrants is $8.1031, the closing bid price of the Company’s Common Stock on December 13, 2021 (and as adjusted for the reverse stock split referenced in Note 1). The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders’ equity within additional paid-in-capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were $11,478 and net proceeds after deducting the placement agent’s fees and other offering expenses paid or payable by the Company were $10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the “Registration Statement”).
Each Warrant is exercisable for one share of Common Stock at an exercise price of $8.1031 per share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.030 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder’s option upon issuance, 9.99%) of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares of Common Stock to the Warrant holder.
In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants.

17
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


Common Stock Warrants
Warrants to purchase 576,261 shares of common stock at a price of $8.1031 per share were acquired in the December 2021 registered-direct offering transaction. The warrants were classified as equity. As a result of the closing of the September 2022 PIPE, a warrant holder elected to exercise their option within 30 days of the closing of the September 2022 PIPE (February 24, 2023) to receive a cash payout for the outstanding warrants in the amount of the Black-Scholes value of each warrant as prescribed in the warrant agreement. The Company paid $800 to this warrant holder on June 23, 2023 and 526,151 were settled as a result. As of March 31, 2024, warrants to purchase 50,110 shares of common stock at a price of $8.1031 per share that were acquired in the December 2021 registered-direct offering transaction remain outstanding.
7. Equity-Based Compensation
2017 Equity Incentive Plan
On September 22, 2017, the Company’s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 194,750 shares of Exicure common stock, which includes 72,330 shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 122,793 that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the “2015 Plan”) and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 153,333 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the “Compensation Committee”). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2023, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 153,333 awards.         
As of March 31, 2024, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 455,765.
Awards granted under the 2017 Plan are contingent on the participants’ continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above.
18
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


Employee Stock Purchase Plan
The 2017 Employee Stock Purchase Plan (the “ESPP”) was adopted by the Board in September 2017 and approved by the Company’s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 250 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee’s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date.
The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 10,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2023, the number of shares of common stock available for issuance under the ESPP increased by 10,000 shares. As of March 31, 2024, there were 61,971 shares available for issuance under the ESPP.
Equity-based compensation expense is classified in the statements of operations as follows:
Three Months Ended
March 31,
20242023
Research and development expense$— $154 
General and administrative expense5 154 
$5 $308 

Unamortized equity-based compensation expense at March 31, 2024 was $27, which is expected to be amortized over a weighted-average period of 1.6 years.
The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The model also requires the input of highly subjective assumptions. No options were granted during the three months ended March 31, 2024. The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the three months ended March 31, 2023:
Three Months Ended
March 31,
2023
Expected term
5.8 to 5.8 years
Risk-free interest rate
3.83% to 3.83%; weighted avg. 3.83%
Expected volatility
101.0% to 101.0%; weighted avg. 101.0%
Forfeiture rate5 %
Expected dividend yield— %


19
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


The expected term is based upon the “simplified method” as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the “simplified method” until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. For stock options granted after December 31, 2021, the expected volatility is based on the volatility of shares of the Company. For stock options granted prior to January 1, 2022, the expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant.
The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2023 are summarized in the table below. No options were granted during the three months ended March 31, 2024.
Fair Value of Underlying Common StockExercise Price of Common Stock Option
Three months ended March 31, 2023
$1.58;
weighted avg. $1.58
$1.58;
weighted avg. $1.58

The weighted-average grant date fair value of common stock options granted in the three months ended March 31, 2023 was $1.26 per common stock option.
A summary of common stock option activity as of the periods indicated is as follows:
OptionsWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (years)Aggregate Intrinsic Value (thousands)
Outstanding - December 31, 202312,115 $4.28 5.4$— 
Granted— — 
Exercised— — 
Forfeited(416)5.51 
Outstanding - March 31, 202411,699 $5.51 5.1$— 
Exercisable - March 31, 202411,699 $5.51 5.1$— 
Vested and Expected to Vest -
March 31, 2024		11,699 $5.51 5.1$— 


20
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


A summary of restricted stock unit activity of the periods indicated is as follows:
Restricted Stock UnitsWeighted-Average Grant Date Fair Value
Unvested balance - December 31, 20233,043 $10.41 
Granted— — 
Vested(296)18.47 
Forfeited(417)3.45 
Unvested balance - March 31, 20242,330 $13.03 
The grant date fair value of restricted stock units is based on the Company’s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company’s common stock. Restricted stock units generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.
8. Income Taxes
The Company incurred a pretax loss in each of the three months ended March 31, 2024 and 2023, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended. The effective tax rate is 0% in each of the three months ended March 31, 2024 and 2023 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.
9. Loss Per Common Share
Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the three months ended March 31, 2024 and 2023.
The following is the computation of loss per common share for the three months ended March 31, 2024 and 2023:
Three Months Ended
March 31,
20242023
Net loss$(829)$(4,407)
Weighted-average basic and diluted common shares outstanding8,650,878 6,288,952 
Loss per share - basic and diluted$(0.10)$(0.70)
21
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period:
As of March 31,
20242023
Options to purchase common stock11,699 203,406 
Restricted stock units2,330 8,784 
Performance stock units— 97,643 
Warrants to purchase common stock50,110 576,261 
10. Fair Value Measurements
ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
Assets measured at fair value on a recurring basis as of March 31, 2024 are as follows:
TotalLevel 1Level 2Level 3
Assets
Cash equivalents:
Money market funds$273 $273 $— $— 
Short-term investments:
Investment in convertible notes receivable— — — — 
Total financial assets$273 $273 $— $— 
    

Assets measured at fair value on a recurring basis as of December 31, 2023 are as follows:
TotalLevel 1Level 2Level 3
Assets
Cash equivalents:
Money market funds$1,629 $1,629 $— $— 
Short-term investments:
Investment in convertible notes receivable— — — — 
Total financial assets$1,629 $1,629 $— $— 
The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company uses the market approach and Level 3 inputs to value its liabilities. There were no liabilities measured at fair value on a recurring basis as of as of December 31, 2023 nor March 31, 2024.


22
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


There were no transfers between Level 1, 2, or 3, during the three months ended March 31, 2024, and 2023. Both observable and unobservable in puts were used to determine fair value of the positions that the Company classified within the Level 3 category. Unrealized gains and losses associated within the Level 3 category include changes in fair value that were attributable to both observable and unobservable inputs.
11. Commitments and Contingencies
Legal Proceedings
On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663. On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti & Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. The parties filed a joint status report noting the mediation efforts taken by the parties. The report also proposes a litigation schedule going forward, which the Court adopted: plaintiff's third amended complaint is due on or before June 28, 2024, and any motion to dismiss is due on or before August 27, 2024, with response due on or before October 8, 2024 and any reply due on or before November 5, 2024. Accordingly, the status hearing set for May 22, 2024 is reset to July 23, 2024.
On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Dr. Giljohann and Mr. Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned Stourbridge Investments LLC v. Exicure, Inc. et al., Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints (collectively, the “Derivative Complaints”) allege that the defendants caused the Company to issue false and/or misleading statements in the proxy statement for its 2021 Annual Meeting of Stockholders regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders.
On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision.
23
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee’s separation from the Company. The parties will proceed with paper discovery and an in-person settlement conference is scheduled for June 26, 2024.
Northwestern University License Agreements
On December 12, 2011, (1) AuraSense, LLC, the Company’s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC’s 2009 license agreement with Northwestern University (“NU”) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the “assigned field”); (2) in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3) in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company’s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee’s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company. In August 2015, the Company entered into a restated license agreement with NU (the “Restated License Agreement”). In February 2016, the Company obtained exclusive license as to NU’s rights in certain SNA technology it jointly owns with NU (the “Co-owned Technology License”). The Company’s license to NU’s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. The Company’s rights and obligations in the Co-owned Technology License agreement is substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as “the Northwestern University License Agreements”). As of March 31, 2024, the Company has paid to NU an aggregate of $11,567 in consideration of each of the obligations described above.
On August 3, 2023, the company received a notice letter (the “Letter”) from counsel for NU alleging the Company breached the Northwestern University License Agreements. The Letter alleges that a lack of development required under the Northwestern University License Agreements is a breach. The Northwestern University License Agreements were subsequently terminated on September 10, 2023 and October 3, 2023, respectively.
Leases
Refer to Note 4, Leases, for a discussion of the commitments associated with the Company’s lease agreements.
12. Related-Party Transactions
Pursuant to a Consulting Agreement, effective as of September 25, 2022, between the Company and Alta Companies LTD (“Alta”), the Company paid Alta $218 on February 27, 2023 for a consulting fee earned as a result of the September 2022 PIPE closing. Paul Kang, a director of the Company since February 2023 and the CEO of the Company since August 2023, is the President of Alta.
13. License Agreement
On February 5, 2024, the Company entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis with a private clinical stage biopharmaceutical company. Under the terms of the agreement, this biopharmaceutical company will receive an exclusive license in the field of hepatitis to all of the Company’s relevant patents. An initial payment of $500 was paid to the Company after the execution of this agreement. This payment was recognized as revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company will also be entitled to modest royalties on future net sales on all licensed technology during the term of the licensed patents. The Company will be responsible for, and make all decisions concerning, the
24
EXICURE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)


preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents.
14. Subsequent Events
On May 3, 2024, the Company executed a promissory note (“Note”) and subsequently received a loan in the amount of $300 from an individual investor. All principal and accrued interest will be due and payable on the earlier of (i) the 1st anniversary of the date of this Note or (ii) upon an event of default, at that time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this Note at 6.0% and is payable at maturity.
On June 3, 2024, the Company executed another promissory note (“DGP Note”) and subsequently received a loan in the amount of $700 from DGP, a related party. All principal and accrued interest will be due and payable on the earlier of (i) the ten-month anniversary of the date of this DGP Note or (ii) upon an event of default, at that time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this DGP Note at 6.0% and is payable at maturity.
25
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K (the “Annual Report”) for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission, or SEC, on June 6, 2024. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks, uncertainties, assumptions and other factors including, but not limited to, those identified in this Quarterly Report on Form 10-Q and those set forth under the section titled “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other SEC filings.
Overview
Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. While the foregoing efforts are continuing with respect to our historical assets, we do not expect they will generate significant value for stockholders. For example, in February 2024, we announced a licensing deal for patents related to one of our historical drug candidates, and received a small, one-time payment and an entitlement to only modest royalties on future sales of the licensed technology that we do not believe will be material. Therefore, we are engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. We are exploring transactions in industries unrelated to our historical operations.
Because we currently have no source of revenue or committed financing, we will require substantial additional funding in the very near term in order to continue to operate and continue our exploration of strategic alternatives and consummate any transactions that we may identify.
Operating, financing, and cash flow considerations
Since our inception in 2011, we have primarily funded our operations through sales of our securities, loans and collaborations. On February 24, 2023, we raised gross proceeds of $5.4 million on the closing of the Private Placement (as defined below) (or net proceeds of approximately $4.6 million after transaction expenses). However, we already used these net proceeds for severance payments, warrant put payments, acquisition of the Notes Receivable, payroll, and general working capital purposes as we pursue strategic alternatives. As of March 31, 2024, our cash and cash equivalents were $0.4 million. Subsequent to March 31, 2024, our cash and cash equivalents have decreased to approximately $0.2 million as of May 31, 2024. We will attempt to redeem the $2.0 million aggregate principal amount of the Notes Receivable in the third quarter of 2024, however, there can be no assurance that we will be able to do so, in the near term or at all. See “Risk Factors – We may not be able to redeem the investment in notes receivable.”
Our current liquidity is not sufficient to continue to fund operations. As a result, there is substantial doubt about our ability to continue as a going concern. Substantial additional financing will be needed in the very near term to fund our operations and exploration of strategic alternatives and pursue any alternatives that we identify. If we are unable to raise capital, the Company may seek bankruptcy protection and/or cease operations in the near term, which may result in the Company’s stockholders receiving no or very little value in respect of their shares of the Company’s common stock.
We expect to seek financing through equity offerings. However, it may be difficult to obtain financing given the Company’s current condition and uncertainty over its future direction. Therefore, we may be unable to raise capital at all or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to continue operations.
26
Recent Developments
Change of Control
On September 26, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with CBI USA, Inc. (“CBI USA”), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of $1.60 per share. The private placement closed on February 24, 2023 (the “Closing Date”).
CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. (“DGP”). On June 23, 2023, DGP exercised its the option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on June 30, 2024.
The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any “group” of which it or they are a member with the right to designate directors to the Company’s board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on June 30, 2024.
Nasdaq Listing Requirements Deficiency Notice
As previously disclosed, the Company has received numerous deficiency notices with respect to various Nasdaq listing requirements in the past year. These related to:
•Compliance with Nasdaq’s minimum bid price rule due to the Company’s stock trading below $1.00 for a sustained period of time. The Company effected a one-for-thirty reverse stock split on June 29, 2022 in order to attempt to raise the stock price. On September 13, 2023, the Company received a delinquency notification that the closing bid price of the Company’s stock traded below $1.00 for the previous 30 consecutive business days. The Company’s stock price has remained below $1.00 since receipt of the notification, which must be cured by September 9, 2024, per the March 12, 2024 extension letter received from Nasdaq.
•Compliance with Nasdaq’s rule requiring stockholders’ equity of at least $2,500,000 based on the Company’s balance sheet as of March 31, 2024. The Company is not in compliance with this requirement based on its March 31, 2024 balance sheet.
•Compliance with Nasdaq’s corporate governance requirements with respect to board and committee composition. The Company has received numerous deficiency notifications with respect to these requirements in the past year. Although the Company believes it is currently in compliance, there can be no assurance it will remain in compliance.
•Compliance with Nasdaq’s requirement to hold an annual meeting. On January 11, 2024, Nasdaq notified the Company that it did not comply with listing requirements by not holding an annual meeting in 2023. The Company received an extension letter on March 12, 2024 from Nasdaq noting it must hold its annual meeting by June 28, 2024.
•On April 17, 2024, the Company received a delinquency notification as it had not filed its Annual Report Form 10-K for the year ended December 31, 2023. The extended deadline for compliance was established by Nasdaq at May 20, 2024, the same deadline for our Form 10-Q for the quarter ended September 30, 2023. The Annual Report Form 10-K was filed on June 6, 2014.
•Although the Company filed its Form 10-Q for the quarter ended September 30, 2023 prior to the extended deadline of May 20, 2024, on May 21, 2024, the Company received a delisting determination from the
27
Nasdaq staff as a result of not filing its Annual Report Form 10-K by the May 20, 2024 deadline and failure to timely file this Form 10-Q. The staff’s delisting determination also noted the failure to hold its 2023 annual meeting as another basis of the delisting determination.
•On May 28, 2024, the Company requested an appeal of the delisting determination to Nasdaq’s hearings panel. A hearing has been scheduled for July 9, 2024. In connection with its request for an appeal, the Company also requested an extended stay on the suspension of trading in the Company’s common stock through the decision of the hearings panel. The stay was granted pending a final decision by the hearings panel.
Even if the Company regains compliance with Nasdaq’s listing requirements and addresses the outstanding deficiency notices to Nasdaq’s satisfaction, there can be no assurance that the Company will remain in compliance with Nasdaq’s requirements and will not be delisted.
Critical Accounting Estimates
We prepare our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.
We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.
Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of Directors. In addition, there are other items within our financial statements that require estimation, but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements. This includes estimates where the nature of the estimate is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the impact of the estimate on financial condition or operating performance is material.
Recent accounting pronouncements not yet adopted
There are no recent accounting pronouncements that the Company has not yet adopted.
28

Results of Operations
Comparison of the Three Months Ended March 31, 2024 and 2023
The following table summarizes the results of our operations for the three months ended March 31, 2024 and 2023:
Three Months Ended
March 31,
(dollars in thousands)20242023Change
Revenue:
Revenue$500 $— 500 100 %
Total Revenue500 — 500 100 %
Operating expenses:
Research and development expense— 1,423 (1,423)(100)%
General and administrative expense1,336 3,116 (1,780)(57)%
Total operating expenses1,336 4,539 (3,203)(71)%
Operating loss(836)(4,539)3,703 (82)%
Other income, net:
     Dividend income4 17 (13)(76)%
     Interest income3 11 (8)(73)%
     Other income, net— 104 (104)(100)%
Total other income, net7 132 (125)(95)%
Net loss before provision for income taxes(829)(4,407)3,578 (81)%
Provision for income taxes— — — — %
Net loss$(829)$(4,407)$3,578 (81)%

Revenue
On February 5, 2024, the Company entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis with a private clinical stage biopharmaceutical company. Under the terms of the agreement, this biopharmaceutical company will receive an exclusive license in the field of hepatitis to all of the Company’s relevant patents. An initial payment of $500 was paid to the Company after the execution of this agreement. The Company will also be entitled to modest royalties on future net sales on all licensed technology during the term of the licensed patents. The Company will be responsible for, and make all decisions concerning, the preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents.

29
Research and development expense
The following table summarizes our research and development expenses incurred during the periods indicated:
Three Months Ended
March 31,		 
(dollars in thousands)20242023Change
Employee-related expense$— $511 $(511)(100)%
Facilities, depreciation, and other expenses— 755 (755)(100)%
Platform and discovery-related expense— 93 (93)(100)%
Clinical development programs expense— 64 (64)(100)%
Total research and development expense$— $1,423 $(1,423)(100)%
Full time employees— 1 (1)

Research and development expense was $0.0 million for the three months ended March 31, 2024, reflecting a decrease of $1.4 million, or 100% from research and development expense of $1.4 million for three months ended March 31, 2023. In 2022, the Company suspended its clinical, preclinical, and discovery program activities and reduced headcount as it began exploring strategic alternatives in April 2023. As a result, after the first quarter of 2023, we determined it was no longer appropriate to record any research and development expenses.
General and administrative expense
Three Months Ended
March 31,
(dollars in thousands)20242023Change
General and administrative expense$1,336 $3,116 (1,780)(57)%
Full time employees5 8 (3)

General and administrative expense was $1.3 million for the three months ended March 31, 2024, representing an decrease of $(1.8) million or (57)%, from $3.1 million for the three months ended March 31, 2023. The decrease for the three months ended March 31, 2024 was mostly due to lower professional fees as a result of reduced operations and higher costs in 2023 from the separation pay of former executives and related stock based compensation expense.
Liquidity and Capital Resources
Since our inception, we have incurred significant operating losses. We generated limited revenue from our collaboration agreements, which have since been terminated. We have funded our operations to date with proceeds received from equity financings and payments received in connection with collaboration agreements, which have since been terminated. Currently we are exploring strategic alternatives and generating no revenue.
As of March 31, 2024, our cash and cash equivalents were $0.4 million as compared to $0.8 million as of December 31, 2023. To date, we have funded our operations primarily with proceeds received from equity financings and to a lesser extent, payments received in connection with collaboration agreements. Subsequent to March 31, 2024, our cash and cash equivalents have decreased to approximately $0.2 million as of May 31, 2024. We will attempt to redeem the $2.0 million aggregate principal amount of the convertible notes receivable in August 2024, however, there can be no assurance that we will be able to do so, in the near term or at all. See “Risk Factors – We may not be able to redeem the investment in convertible notes receivable.”
We incurred net losses of approximately $0.8 million and $4.4 million for the three months ended March 31, 2024 and 2023, respectively. We expect to incur significant expenses and negative cash flows for the foreseeable future.
30
Our current liquidity is not sufficient to continue to fund operations. As a result, there is substantial doubt about our ability to continue as a going concern. Substantial additional financing will be needed in the very near term to fund our operations and there is no certainty we will obtain such financing. If we are unable to raise capital, we will be unable to continue operations. We may need to seek bankruptcy protection and/or cease operations in the near term, which may result in our stockholders receiving no or very little value in respect of their shares of our common stock.
See “Funding Requirements” below for additional information on our future capital needs.

Cash Flows
The following table shows a summary of our cash flows for the three months ended March 31, 2024 and 2023:
Three Months Ended
March 31,
(in thousands)20242023
(unaudited)
Net cash used in operating activities$(450)$(3,318)
Net cash provided by investing activities— 106 
Net cash provided by financing activities— 4,595 
     Net (decrease) increase in cash, cash equivalents, and restricted cash$(450)$1,383 

Operating activities
Net cash used in operating activities was $0.5 million and $3.3 million for the three months ended March 31, 2024 and 2023, respectively. The decrease in cash used in operating activities for the three months ended March 31, 2024 of $2.9 million was due to the reduction of operating activities and lower headcount.
Investing activities
Net cash used in investing activities was $0.0 million and provided by investing activities was $0.1 million for the three months ended March 31, 2024 and 2023, respectively. The decrease in cash provided by investing activities of $0.1 million was primarily due to the lack of investing activities and a sale of scientific equipment in 2023.
Financing activities
Net cash provided in financing activities of $0.0 million for three months ended March 31, 2024. The decrease of $4.6 million is due to the funds received from the Private Placement in February 2023.
Funding Requirements
We will need to obtain substantial additional funding in the very near term to continue operations. If we are unable to raise capital at all or on acceptable terms, we would be unable to continue operations.
Our existing cash and cash equivalents are not sufficient to enable us to fund our operating expenses. Our future capital requirements are difficult to forecast and will depend on many factors, including:
•the results of our exploration of strategic alternatives, including any potential transactions;
•the results of any future or pending litigation against the Company;
•the extent to which we encounter increased costs as a result of global and macroeconomic conditions, including rising inflation and interest rates, supply chain disruptions, fluctuating exchange rates, and increases in commodity, energy and fuel prices; and
31
•unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company.
Until such time, if ever, as we can generate substantial revenue, we expect to finance our cash needs primarily through equity offerings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. Further, the global financial markets have experienced significant disruptions over the past couple of years due to the COVID-19 pandemic, the ongoing conflict between Russia and Ukraine, and worsening global macroeconomic conditions, including actions taken by central banks to counter inflation, volatility in the capital markets and related market uncertainty, may impact our ability to obtain additional financing when needed on favorable terms or at all. Any further disruption or slowdown in the global financial markets and economy may negatively affect our ability to raise funding through equity or debt financings on attractive terms or at all, which could in the future negatively affect our operations.
Going Concern
In accordance with Accounting Standards Codification 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. In the absence of a significant source of recurring revenue, our continued viability is dependent on our ability to continue to raise additional capital to finance our operations. As discussed above, there are substantial uncertainties about our ability to raise such financing.
Contractual Obligations and Commitments
There have been no material changes to our contractual obligations and commitments from those described in our Annual Report.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.
Limitations on Effectiveness of Controls
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
We maintain “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their
32
objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weakness described below.
Material Weakness in Internal Control Over Financial Reporting
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.
Management identified material weaknesses in the Company’s internal control over financial reporting related to the following:
1.The precision of management’s review of the Statement of Operations, resulting in inappropriately classifying certain general and administrative expenses as research and development expenses for the three months ended March 31, 2023, and three and six months ended June 30, 2023.
2.Management’s review of the accounting treatment of non-routine activities, specifically the Company’s analysis of the AFS debt securities.
3.The Company failed to design and implement controls around all accounting and information technology processes and procedures.
These matters have been reviewed with our Audit Committee.
Remediation Plan
We are evaluating the material weakness and are developing a plan of remediation to strengthen the effectiveness of the design and operation of our internal control environment. The remediation plan will include enhancing our review procedures within our accounting department, implementing additional review procedures with respect to accumulation and evaluation of information that is known or knowable to the Company at the time, and applying that information to the applicable accounting guidance. Subject to our ability to obtain additional financing and the results of our review of strategic alternatives, we will also consider whether additional personnel are necessary.
Changes in Internal Control over Financial Reporting
Other than described above, there were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



33
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663. On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti & Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. The parties filed a joint status report noting the mediation efforts taken by the parties. The report also proposes a litigation schedule going forward, which the Court adopted: plaintiff's third amended complaint is due on or before June 28, 2024, and any motion to dismiss is due on or before August 27, 2024, with response due on or before October 8, 2024 and any reply due on or before November 5, 2024. Accordingly, the status hearing set for May 22, 2024 is reset to July 23, 2024.
On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Messrs. Giljohann and Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned Stourbridge Investments LLC v. Exicure, Inc. et al., Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints, or collectively, the Derivative Complaints, allege that the defendants caused the Company to issue false and/or misleading statements in its 2021 proxy statement regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders.
On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s current officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision.
On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee’s separation from the Company. The parties will proceed with paper discovery and an in-person settlement conference is scheduled for June 26, 2024.
We may also be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome,
34
litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
35
Item 1A. Risk Factors.
In addition to other information contained in this Quarterly Report on Form 10-Q, the following risks should be considered in evaluating our business and future prospects and an investment in our common stock. The risks and uncertainties described below are not the only ones we face. If any of the following risks and uncertainties develops into actual events, our business, financial condition, results of operations and cash flows could be materially adversely affected. In that case, the price of our common stock could decline and you may lose all or part of your investment.
Risks Related to Our Business
Our exploration of strategic alternatives may not be successful.

Given the Company’s current focus to explore growth through strategic transactions with potential partners, the Company’s ability to execute its current business plan depends on its ability to obtain additional funding via a strategic transaction or a series of strategic transactions, or to obtain funding to support such a transaction. We currently have no source of revenues or committed financing, and our financial resources are limited to our cash and cash equivalents. Substantial additional funding is needed in the very near term. With respect to our efforts to maximize value from historical assets, while those efforts are continuing, based on the interest we have received to date we do not think it is likely they will generate significant value.
The Company plans to continue pursuing strategic alternatives, however, there can be no assurance that the Company will have sufficient resources or obtain additional financing necessary to complete this effort. Even if we can obtain financing, we may not be able to consummate such a transaction in a timely manner or at all or in a manner that would not adversely impact our business. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. Strategic transactions are complex and time-consuming to identify, evaluate, negotiate and consummate in compliance with applicable laws and Nasdaq requirements. Our board and management do not have meaningful experience executing this type of endeavor in the U.S. public markets. Even if we are successful in entering into a strategic transaction, the terms and conditions of that transaction may restrict us from entering into future agreements with other potential collaborators. Additionally, such strategic transactions may not be favorable to investors nor deliver any anticipated benefits by the time of business integration.
We need to obtain substantial funding in the very near term in order to continue operations and our exploration of strategic alternatives.

We require significant capital resources in order to continue to operate our business and conduct our exploration of strategic alternatives, and our very limited liquidity could materially and adversely affect our business operations. Because we have no current source of revenue or committed financing, our current available cash and cash equivalents provide us with very limited liquidity. Our existing cash and cash equivalents are not sufficient for us to continue to fund our business operations. Substantial additional funding is needed in the very near term. Any such required additional capital may not be available on reasonable terms, if at all, due to a variety of factors, including uncertainty about the future direction of the Company and investor reaction to our new controlling stockholders and board and management composition, as well as broader conditions in the economy and capital markets, including recent volatility caused by inflation, questions about bank stability and other factors. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend our operating runway is limited. Without sufficient additional capital funding in the very near term, we may be required, among other things, to seek bankruptcy protection and/or cease operations.
We may not be able to redeem the investment in convertible notes receivable.

In March 2024, the Company notified the issuer of the investment in convertible notes receivable that it was exercising its redemption right with respect to the entire principal amount of the investment in convertible notes receivable after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of $2.090 million (representing the principal amount plus 4.5% per annum yield to the redemption date).
The investment in convertible notes receivable indicate that the Company may request redemption on the first anniversary of the issue date. However, the investment in convertible notes receivable contain schedules for dates of redemption notices and redemption prices that do not contemplate a first redemption date until three months after the first anniversary of the issue dates. Although the Company believes this was a clear error and is inconsistent with the plain language that the investment in convertible notes receivable are redeemable on the first anniversary of their issue dates,
36
the issuer has taken the position that the investment in convertible notes receivable are not redeemable until August 3, 2024 and August 16, 2024.
The Company expects to continue to seek to redeem the investment in convertible notes receivable as soon as practicable. However, there can be no assurance that the Company will be able to do so, in the near term or at all. If we are unable to redeem the investment in convertible notes receivable, or otherwise recognize value from them, it will adversely impact our financial condition and prospects.
Our controlling stockholders, executive officers and members of our board, have limited experience controlling or governing a public company operating in the United States.
Our controlling stockholders have not previously controlled a U.S. public company. In addition, no members of the board or our chief executive officer or chief financial officer have experience serving as directors or management of a U.S. publicly traded company. This could make it difficult to ensure that the Company complies with all applicable laws and stock exchange requirements, maintains adequate internal and disclosure controls and appropriately assesses and manages risk. This concern is exacerbated by the limited resources the Company has following recent reductions in force, and if there are further reductions in force or members of management leave the Company, it may be very difficult to manage this risk. The transitional state of the Company and ongoing exploration of strategic alternatives also exacerbates the challenging environment in this respect. If the board of directors does not successfully or efficiently manage their roles and responsibilities, including the significant regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of investors, our prospects may be adversely impacted. In addition, against this backdrop, it may be difficult to earn the confidence of prospective investors or strategic partners, threatening our ability to obtain much needed financing and hindering our exploration of strategic alternatives.
Turnover of our board and senior management, and any inability to attract and retain qualified management and other key personnel, could impair our ability to implement our business plan.
As we continue our exploration of strategic alternatives, and potentially pursue transactions involving new business lines or industries, we may experience additional turnover in our board and senior management. Departures of members of our senior management team and board members have created, and will create if they continue, significant continuity risks and challenges to our ability to operate our business, assess and manage risks and comply with applicable laws. If key members of our senior management team depart, it will be important that we attract and retain qualified managers promptly and develop and implement an effective succession plan. We expect to face significant competition in attracting experienced executives and other key personnel, and there can be no assurance that we will be able to do so. In addition, there are significant uncertainties as to how our transitional state of operations, financial condition and related matters will impact our ability to attract the necessary personnel and manage these succession risks. Our urgent need to raise capital and engage with potential partners in strategic transactions magnify these risks. If we are unable to adequately address these concerns in the near term, and earn the confidence of potential investors and/or business partners, our prospects and financial condition would be adversely impacted.
Our consolidated financial statements have been prepared assuming that we will continue as a going concern.
Our ability to continue as a going concern will require us to obtain additional funding. Based on our current operating plans and existing working capital at March 31, 2024, our current liquidity is not sufficient to continue to fund operations. As a result, there is substantial doubt about our ability to continue as a going concern. Substantial additional financing will be needed by us in the very near term to fund our operations and exploration of strategic alternatives. The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors and employees. Obtaining additional financing contains risks, including:
•additional equity financing may not be available to us on satisfactory terms and any equity we are able to issue could lead to dilution for current stockholders;
•loans or other debt instruments may have terms and/or conditions, such as interest rate, restrictive covenants and control or revocation provisions;
•the current environment in capital markets combined with our capital constraints may prevent us from being able to obtain adequate debt financing; and
•if we fail to obtain required additional financing to grow our business we may need to seek bankruptcy protection in the near term.
37
We currently do not comply with the Nasdaq continued listing requirements and have received a delisting determination notice from the Nasdaq staff. Our common stock may be delisted from Nasdaq which could negatively impact the price of our common stock, liquidity and our ability to access the capital markets.
Our common stock is currently listed on Nasdaq under the symbol “XCUR.” As previously disclosed, the Company has received numerous deficiency notices with respect to various Nasdaq listing requirements in the past year and recently received a delisting determination from the Nasdaq staff. These related to, or may in the future relate to:
•Compliance with Nasdaq’s minimum bid price rule due to the Company’s stock trading below $1.00 for a sustained period of time. The Company effected a one-for-thirty reverse stock split on June 29, 2022 in order to attempt to raise the stock price. On September 13, 2023, the Company received a delinquency notification that the closing bid price of the Company’s stock traded below $1.00 for the previous 30 consecutive business days. The Company’s stock price has remained below $1.00 since receipt of the notification, which must be cured by September 9, 2024, per the March 12, 2024 extension letter received from Nasdaq.
•Compliance with Nasdaq’s rule requiring stockholders’ equity of at least $2,500,000 based on the Company’s balance sheet as of March 31, 2024. The Company is not in compliance with this requirement based on its March 31, 2024 balance sheet.
•Compliance with Nasdaq’s corporate governance requirements with respect to board and committee composition. The Company has received numerous deficiency notifications with respect to these requirements in the past year. Although the Company believes it is currently in compliance, there can be no assurance it will remain in compliance.
•Compliance with Nasdaq’s requirement to hold an annual meeting. On January 11, 2024, Nasdaq notified the Company that it did not comply with listing requirements by not holding an annual meeting in 2023. The Company received an extension letter on March 12, 2024 from Nasdaq noting it must hold its annual meeting by June 28, 2024
•On April 17, 2024, the Company received a delinquency notification as it had not filed its Annual Report Form 10-K for the year ended December 31, 2023. The extended deadline for compliance was established by Nasdaq at May 20, 2024, the same deadline for our Form 10-Q for the quarter ended September 30, 2023, which had yet to be filed at the time.
•Although the Company filed its Form 10-Q for the quarter ended September 30, 2023 prior to the extended deadline of May 20, 2024, on May 21, 2024, the Company received a delisting determination from the Nasdaq staff as a result of not filing its Annual Report Form 10-K by the May 20, 2024 deadline and failure to timely file this Form 10-Q. The staff’s delisting determination also noted the failure to hold its 2023 annual meeting as another basis of the delisting determination.
•On May 28, 2024, the Company requested an appeal of the delisting determination to Nasdaq’s hearings panel. A hearing has been scheduled for July 9, 2024. In connection with its request for an appeal, the Company also requested an extended stay on the suspension of trading in the Company’s common stock through the decision of the hearings panel. The stay was granted pending a final decision by the hearings panel.
We may not be successful in our appeal or be able to regain compliance with Nasdaq’s listing requirements and our failure to do so may result in the delisting of our Common Stock by Nasdaq. Even if the Company is successful in our appeal and regains compliance with Nasdaq’s listing requirements and addresses the outstanding deficiency notices to Nasdaq’s satisfaction, there can be no assurance that the Company will remain in compliance with Nasdaq’s requirements and will not be delisted.
If Nasdaq suspends or delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant negative consequences including:
•limited availability of market quotations and liquidity for our securities;
•a determination that the common stock is a “penny stock” which would require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of common stock;
•a limited amount of analyst coverage, if any; and
38
•a decreased ability to issue additional securities or obtain additional financing in the future.
Suspension or delisting from Nasdaq could also result in other negative consequences, including the potential loss of institutional investor interest and make obtaining new financing much more challenging. In addition, fewer strategic opportunities may be available, particularly from counterparties that are interested in combining with a listed company.
We have a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.
Between our inception in June 2011 and the Company’s decision to engage in a broader exploration of strategic alternatives, we devoted our resources to the development of SNA technology, and are currently exploring out-licensing opportunities and strategic alternatives to maximize stockholder value. We have had significant operating losses since our inception. As of March 31, 2024, we have generated an accumulated deficit of $209.2 million, including $18,837 of additional paid-in capital reclassed to accumulated deficit upon C-corporation conversion. For the three months ended March 31, 2024 and 2023, our net loss was $0.8 million and $4.4 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations.
We have not generated, and do not expect to generate, any product revenue for the foreseeable future and currently have no source of revenue or committed financing, and we expect to continue to incur significant operating losses for the foreseeable future. The amount of future losses is uncertain. Our future financial performance and condition are substantially dependent on the results of our ongoing exploration of strategic alternatives, and we cannot predict whether we will be successful.
We are pursuing asset out-licenses, asset sales and similar strategic transactions with respect to our historical assets. There can be no assurance that we will be successful in executing such a strategic transaction and at this point we do not expect these efforts to generate significant value for our stockholders.
Our internal computer systems, or those of contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our business operations.
Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future e, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations.
To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed.
Our information technology systems could face serious disruptions that could adversely affect our business.
Our information technology and other internal infrastructure systems, including corporate firewalls, servers, documents storage systems, backup systems, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our operations.
Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our information technology systems.
We are increasingly dependent on our information technology systems and infrastructure for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business information and personal information in connection with business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack or unauthorized access and use by third parties with a wide range of motives and expertise, including organized criminal groups,
39
“hacktivists,” patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology systems and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.
The pervasiveness of cybersecurity incidents in general and the risks of cyber-crime are complex and continue to evolve. Although we are making significant efforts to maintain the security and integrity of our information systems and are exploring various measures to manage the risk of a security breach or disruption, there can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging. Despite the implementation of security measures, our internal computer systems and those of our employees, contractors and consultants are vulnerable to damage or interruption from computer viruses, unauthorized or inappropriate access or use, natural disasters, pandemics (including COVID-19), terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss or compromise of preclinical data for our therapeutic candidates could result in delays in our regulatory filings and development efforts, as well as delays in the commercialization of our products, and significantly increase our costs. To the extent that any disruption, security breach or unauthorized or inappropriate use or access to our systems were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, including but not limited to patient, employee or vendor information, we could incur notification obligations to affected individuals and government agencies, liability, including potential lawsuits from patients, collaborators, employees, stockholders or other third parties and liability under foreign, federal and state laws that protect the privacy and security of personal information, and the development and potential commercialization of our therapeutic candidates could be delayed. Existing insurance arrangements may not provide protection for the costs that may arise from such loss or damage. Any long-term disruption in our ability to access our information technology systems could have a material adverse effect on our operations, our business, results of operations and stock price.
Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences.
Our current operations are located in our facilities situated in Chicago, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects.
If we continue to fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. However, while we remain a non-accelerated filer or an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.
During the evaluation and testing process, we identified material weaknesses as described under Part I, Item 4 of this Form 10-Q. If we fail to remediate that material weakness, or if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Further, we may in the future discover additional weaknesses in our system of internal financial and accounting controls and procedures that could result in additional material misstatement of our financial statements. Moreover, our internal controls over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Moreover, we are aware that the remote working arrangements implemented in connection with the COVID-19
40
pandemic potentially present new areas of risk, and we continue to carefully monitor any impact to our internal controls and procedures.
Our limited resources and recent reductions in force, as well as the turnover in our board of directors and the potential for future management changes, present significant continuity risk and could impact our ability to remediate our material weaknesses and maintain effective internal control over financial reporting in the future.
If we are unable to remedy our material weaknesses and assert that our internal control over financial reporting is effective, investors could lose confidence in the reliability of our financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.
The restatement of our prior quarterly financial statements may affect stockholder and investor confidence in us or harm our reputation, and may subject us to additional risks and uncertainties, including increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions or investigations.
Management identified material weaknesses in the Company’s internal control over financial reporting and restated its 2023 first quarter and second quarter unaudited interim condensed consolidated financial statements via Form 10-Q/A’s. As a result of the restatement, we have incurred, and may continue to incur, unanticipated costs for accounting and legal fees in connection with, or related to, such restatement. In addition, such restatement could subject us to a number of additional risks and uncertainties, including the increased possibility of legal proceedings and inquiries, sanctions or investigations by the SEC or other regulatory authorities. Any of the foregoing may adversely affect our reputation, the accuracy and timing of our financial reporting, or our business, results of operations, liquidity and financial condition, or cause stockholders, investors, members and customers to lose confidence in the accuracy and completeness of our financial reports or cause the market price of our common stock to decline.
Risks Related to Ownership of Our Common Stock
The influence of our significant stockholders could make our Common Stock less attractive to some investors or otherwise harm the trading price of our Common Stock.
CBI USA and DGP collectively own approximately 45% of outstanding Common Stock and exercise significant influence over us. We previously had been a “controlled company” under the corporate governance rules for Nasdaq-listed companies and still do not have a majority independent board based on the phase-in requirements for companies after they lose “controlled company” status. Members of our board and management are directly affiliated with CBI and DGP. Investors may be hesitant to invest in the Company given the influence of CBI and DGP. In addition, should the interest or interests of our controlling stockholders differ from those of other stockholders, the other stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance rules for Nasdaq-listed companies.
Additionally, it is possible we could pursue strategic or financing transactions with our controlling stockholders or their affiliates. The interests of the controlling stockholders and other stockholders would diverge in this case, and the lack of an independent board to evaluate such a transaction could adversely impact other stockholders. These conflicts of interest (or the perception that they could occur) might adversely affect our business and prospects for obtaining financing or completing a strategic transaction.
For so long as CBI USA and DGP own a significant stake, they (and/or their transferees) will have substantial control over the elections of our directors and to approve any other corporate action requiring the affirmative vote of holders of a majority of the outstanding shares of our Common Stock. This could deter investment in the Company and adversely impact our stock price and ability to obtain financing. These impacts may be more pronounced in the near term as investors assess the direction of the Company under the control of CBI USA and DGP and the actions of the new board and management. DGP’s recently announced agreement to sell its shares to a third party could also deter investment as it creates uncertainty as to the transferee’s intentions with respect to the Company. If DGP’s sale is completed, the third party transferee would become the Company’s largest stockholder.
Potential partners considering engaging in a strategic transaction with the Company could have similar concerns. Given our urgent need for additional funding and/or to complete a strategic transaction, it is imperative that our controlling stockholders and our board and management earn the confidence of investors and potential partners in the near term and there is no assurance this will occur.
The market price of our common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them.
41
Our stock price will continue to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by a variety of factors, including the other risks described in this section titled “Risk Factors” and the following:
•our ability or inability to raise additional capital and the terms on which we raise it;
•the development, execution and announcement of any proposed strategic alternative;
•investors may react negatively to our controlled company status and the influence of our controlling stockholder or our reconstituted board and/or our uncertain business strategy;
•strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;
•we are unable to achieve the perceived benefits of our Company as rapidly or to the extent anticipated by financial or industry analysts; and
•changes in general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic.
In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors, such as those related to the COVID-19 pandemic, Russia’s invasion of Ukraine, and the Israel/Hamas war and retaliatory actions taken by the United States, NATO and others, may seriously harm the market price of our common stock, regardless of our operating performance.
Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.
Until such time, if ever, as we can generate substantial revenues, we expect to attempt to finance our cash needs through a combination of equity offerings and debt financings. As discussed elsewhere, it may be very challenging to obtain equity or debt financing given the current transitional state of the Company. However, to the extent that we raise additional capital through the issuance of shares or other securities convertible into shares, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities.
We cannot be certain if the reduced reporting requirements applicable to us will make our common stock less attractive to investors.
We were an “emerging growth company” as defined in the JOBS Act until December 31,2023. As such, we took advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (2) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we were only required to provide two years of audited financial statements. Even though we no longer qualify as an emerging growth company as of 2024, we still qualify as a “smaller reporting company” and a “non-accelerated filer” which allows us to continue to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.
Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.
Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on
42
actions by written consent of our stockholders, and the ability of the Board of Directors of the Company, or the Board, to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the Board, which is responsible for appointing the members of management.
Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any of the following types of actions or proceedings under Delaware statutory or common law: derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claims for which a court or forum other than the Court of Chancery has exclusive jurisdiction or for which the Court of Chancery does not have subject matter jurisdiction. Furthermore, Section 22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated certificate of incorporation also provides that any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation.
This choice of forum provision may limit our stockholders’ ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. If a court were to find this exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in any action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could have a material adverse effect on our business, financial condition or results of operations.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
We have incurred substantial losses during our history and do not expect to be profitable in the near future, if ever. Our net operating loss, or NOL, carryforwards generated in tax years beginning on or before December 31, 2017, are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Cuts and Jobs Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is be limited to 80% of taxable income. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change NOL, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past. We completed a review of our changes in ownership through December 31, 2022 and determined that we experienced an “ownership change” within the meaning of Section 382(g) during the fourth quarter of 2022. This ownership change has and will continue to subject our net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset our taxable income in periods following the ownership change.
43

We determined that at the date of the 2022 ownership change, we had a net unrealized built-in loss (“NUBIL”). The NUBIL was determined based on the difference between the fair market value of our assets and their tax basis at the ownership change date. Because of the NUBIL, certain deductions recognized during the five-year period beginning on the date of the IRC Section 382 ownership change (the "recognition period") are subject to the same limitation as the net operating loss carryforwards or certain other deductions.
As of December 31, 2023, we determined that we ceased operations of our historical business enterprise which subjects us to a zero limitation as defined under IRC Section 382(c). Therefore, we are restricted in our ability to use any of the historical net operating losses that occurred before the most recent ownership change in the 4th quarter of 2022.
General Risk Factors
FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our stock due to our low stock price.
The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, which we believe they are, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock.
If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. Our research coverage by securities and industry analysts is currently limited. In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, security analysts of brokerage firms may not provide wider coverage of our Company. In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development. The failure to receive wider research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted.
In the event we obtain wider securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.


44
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.
None.

Item 4. Mine Safety Disclosures.
Not applicable.

Item 5. Other Information.
During the quarter ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
45
Item 6. Exhibits
Incorporated by Reference
Exhibit
No.
Exhibit Description 
FormExhibit No.Filing DateFile No.
3.1

8-K3.2
10/02/17
 000-55764
3.210-K3.3
3/11/21
001-39011
3.38-K3.106/29/22001-39011
3.48-K3.4
10/02/17
000-55764
31.1*
31.2*
32.1**
101.INS*Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


* Filed herewith.
46
** The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exicure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.

47
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: June 17, 2024
EXICURE, INC.
By:/s/ Paul Kang
Paul Kang
Chief Executive Officer
By:/s/ Jiyoung Hwang
Jiyoung Hwang
Chief Financial Officer
By:/s/ Joshua Miller
Joshua Miller
Chief Accounting Officer


48
 EX-31.1 2 exicureexhibit311-33124.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS
I, Paul Kang, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: June 17, 2024
/s/ Paul Kang
Paul Kang
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 exicureexhibit312-33124.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS
I, Jiyoung Hwang, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: June 17, 2024
/s/ Jiyoung Hwang
Jiyoung Hwang
Chief Financial Officer
(Principal Financial Officer)

 EX-32.1 4 exicureexhibit321-33124.htm EX-32.1 Document

Exhibit 32.1
SECTION 1350 CERTIFICATIONS*
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Paul Kang, Chief Executive Officer of Exicure, Inc. (the “Company”), and Jiyoung Hwang, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:
1. The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: June 17, 2024
IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 17th day of June, 2024.
/s/ Paul Kang/s/ Jiyoung Hwang
Paul KangJiyoung Hwang
Chief Executive Officer
Chief Financial Officer
(Principal Executive Officer)
(Principal Financial Officer)
 
*This certification accompanies the Quarterly Report on Form 10-Q, to which it relates is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Exicure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.

 EX-101.SCH 5 xcur-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Description of Business, Basis of Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Investment in Convertible Notes Receivable link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Supplemental Balance Sheet Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Leases - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Leases - Sublease Receipts (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Investment in Convertible Notes Receivable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Equity-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Loss Per Common Share - Schedule of Computation of loss per common share (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Commitment and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Related-Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 xcur-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 xcur-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 xcur-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Schedule of Accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Research and development expense Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Maximum contribution amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Unvested balance - beginning of period (in shares) Unvested balance - end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Third Party Sale of Company Stock Third Party Sale Of Company Stock [Member] Third Party Sale Of Company Stock MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Exercisable, weighted-average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Total other income, net Nonoperating Income (Expense) Promissory Note Promissory Note [Member] Promissory Note Commitments and Contingencies (Note 11) Commitments and Contingencies Prepaid insurance Prepaid Insurance, Noncurrent Prepaid Insurance, Noncurrent Prepaid software Prepaid Software, Current Prepaid Software, Current Insider Trading Policies and Procedures [Line Items] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Aggregate Intrinsic Value (thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Proceeds from common stock offering Proceeds from Issuance of Common Stock Other noncurrent assets Increase (Decrease) in Other Noncurrent Assets Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Description of Business, Basis of Presentation and Going Concern Business Description and Basis of Presentation [Text Block] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Vesting of restricted stock units and related repurchases (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Common Stock And Accompanying Warrant Common Stock And Accompanying Warrant [Member] Common Stock And Accompanying Warrant Diluted loss per common share (in dollars per share) Loss per share - diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Pro rata accrual Registration Rights Agreement, Pro Rata Accrual Registration Rights Agreement, Pro Rata Accrual Vested and expected to vest, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Shares outstanding, beginning period (in shares) Shares outstanding, ending period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Proceeds from patent license agreement Proceeds From Patent License Agreement Proceeds From Patent License Agreement Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Warrants settled (in shares) Class Of Warrant Or Right, Number Of Securities Settled In Period Class Of Warrant Or Right, Number Of Securities Settled In Period Employee Stock Employee Stock [Member] Non-employee Director Non-employee Director [Member] Non-employee Director [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Investment in Convertible Notes Receivable Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Exercise (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Computation of Loss per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Amount of transaction Related Party Transaction, Amounts of Transaction Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses Increase (Decrease) in Accrued Liabilities Exercise price of common stock option (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Warrants issued in sale of stock (in shares) Sale Of Stock, Number Of Warrants Issued In Transaction Sale Of Stock, Number Of Warrants Issued In Transaction Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Common stock, voting rights for each share Common Stock, Voting Rights For Each Share Common Stock, Voting Rights For Each Share Measurement Frequency [Axis] Measurement Frequency [Axis] Warrant Warrants to purchase common stock Warrant [Member] Lease liability, noncurrent Operating Lease, Liability, Noncurrent Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Restricted Stock Unit Awards Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Monthly vesting percentage (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage Operating lease, estimated rental payment over lease term Lessee, Operating Lease, Estimated Rental Payment Over Original Term Lessee, Operating Lease, Estimated Rental Payment Over Original Term Income Statement Location [Axis] Income Statement Location [Axis] Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Schedule of Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Lease Costs Lease, Cost [Table Text Block] Registration rights agreement, liquidation damages payable as a percent of amount invested, if filed late (as a percent) Registration Rights Agreement, Liquidation Damages Payable As A Percent Of Amount Invested, If Filed Late Registration Rights Agreement, Liquidation Damages Payable If Filed Late, As A Percent Of Amount Invested Research and development expense Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Number of shares issued for each vested restricted stock unit (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting Notes Receivable, One Notes Receivable, One [Member] Notes Receivable, One Reclassification of common stock warrants to liability Reclassification Of Common Stock Warrants To Liability Reclassification Of Common Stock Warrants To Liability Third Party Third Party [Member] Third Party Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative expense General and Administrative Expense [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Property and equipment, gross Property, Plant and Equipment, Gross Weighted-Average Remaining Contractual Term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Related-Party Transactions Related Party Transactions Disclosure [Text Block] CBI USA, Inc CBI USA, Inc [Member] CBI USA, Inc Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Purchase price (in dollars per share) Sale Of Stock And Warrants, Price Per Share Sale Of Stock And Warrants, Price Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Pro rata payment Registration Rights Agreement, Pro Rata Payment Registration Rights Agreement, Pro Rata Payment Lease liability Operating Lease, Liability, Current Proceeds from sale or maturity of available-for-sale securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents, and restricted cash - beginning of period Cash, cash equivalents, and restricted cash - end of period Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Sales price of shares issued in transaction (in dollars per share) Sale of Stock, Price Per Share Private Placement Private Placement [Member] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Operating lease costs Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Total financial assets Assets, Fair Value Disclosure Performance stock units Performance Based Restricted Stock [Member] Performance Based Restricted Stock Consideration for stock transaction Sale of Stock, Consideration Received on Transaction DGP Co. Ltd DGP Co. Ltd [Member] DGP Co. Ltd Number of additional shares allowable annually under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan Vesting percentage (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Share-based Payment Arrangement, Option Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Prepaid franchise tax Prepaid Franchise Tax Prepaid Franchise Tax Compensation expense recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Depreciation and amortization Depreciation, Amortization and Accretion, Net Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Short term lease costs Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Initial Employee Stock Option Initial Employee Stock Option [Member] Initial Employee Stock Option [Member] Subsequent Event Subsequent Event [Member] Maximum ESPP contribution rate as a percentage of compensation (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Restricted cash Restricted Cash, Noncurrent Income Statement [Abstract] Income Statement [Abstract] Issuance of common stock, net (in shares) Stock Issued During Period, Shares, New Issues Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Related Party [Domain] Related Party, Type [Domain] Sublease amounts paid to landlord Sublease Income Number of shares exercisable for each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Unvested balance - beginning of period (in dollars per share) Unvested balance - end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Operating lease, number of extensions Lessee, Operating Lease, Number of Extensions Lessee, Operating Lease, Number of Extensions Prepaid professional fees Prepaid Professional Fees, Current Prepaid Professional Fees, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Stated yield Debt Securities, Available-for-Sale, Stated Yield Debt Securities, Available-for-Sale, Stated Yield Total lease costs Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Registration rights agreement, required filing term Registration Rights Agreement, Required Filing Term Registration Rights Agreement, Required Filing Term Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Non-cash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Debt instrument, face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Aggregate consideration paid to NU for agreement obligations Aggregate Payments Made To Date For License Agreements Aggregate Payments Made To Date For License Agreements Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Operating lease, cash payments Operating Lease, Payments Schedule of Equity-Based Compensation Expense Classification in Statement of Operations Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Chicago Chicago [Member] Chicago PEO PEO [Member] Percentage of ownership after transaction (as a percent) Sale of Stock, Percentage of Ownership after Transaction Pre-Funded Warrants Pre-Funded Warrants [Member] Pre-Funded Warrants Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Payment of common stock financing costs Payments Of Common Stock Financing Costs Payments Of Common Stock Financing Costs Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Vested and expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Total liabilities Liabilities Number of additional shares authorized, potential maximum additional shares (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vesting [Domain] Vesting [Domain] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Title of Individual [Axis] Title of Individual [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 8,650,950 issued and outstanding, March 31, 2024; 8,650,753 issued and outstanding, December 31, 2023 Common Stock, Value, Issued General and administrative expense General and Administrative Expense Registration rights agreement, liquidation damages payable if filed late, measurement term Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term Amortization of right-of-use asset Operating Lease, Right-of-Use Asset, Periodic Reduction Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Face value conversion percentage Debt Securities, Available-for-Sale, Face Value Conversion Percentage Debt Securities, Available-for-Sale, Face Value Conversion Percentage All Individuals All Individuals [Member] Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Dividend income Investment Income, Dividend Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Percentage of shares subsequently sold at closing Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold PEO Name PEO Name Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Prepaid insurance Prepaid Insurance Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Consideration received, gross Sale Of Stock, Consideration Received On Transaction, Gross Sale Of Stock, Consideration Received On Transaction, Gross Schedule of Prepaid and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Exicure OpCo 2015 Equity Incentive Plan Exicure OpCo 2015 Equity Incentive Plan [Member] Exicure OpCo 2015 Equity Incentive Plan [Member] Accrued other expenses Other Accrued Liabilities, Current Furniture and fixtures Furniture and Fixtures [Member] Interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Restricted cash included in other noncurrent assets Restricted Cash and Cash Equivalents Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Subsequent Events [Abstract] Net loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net proceeds Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable Sublease percentage of office space subtenant (as a percent) Lessee, Operating Sublease, Percentage Of Office Space Subleased Lessee, Operating Sublease, Percentage Of Office Space Subleased Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Outstanding beginning balance (in dollars per share) Outstanding ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Loss Per Common Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Operating lease area Lessee, Operating Lease, Lease Area Lessee, Operating Lease, Lease Area Operating lease, contract term Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Schedule of Common Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price CBI USA & DGP Co. Ltd CBI USA & DGP Co. Ltd [Member] CBI USA & DGP Co. Ltd Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Payments for minimum statutory tax withholding related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Net cash provided by provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Other income, net: Nonoperating Income (Expense) [Abstract] Other noncurrent assets Other noncurrent assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information [Abstract] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic loss per common share (in dollars per share) Loss per share - basic (in dollars per share) Earnings Per Share, Basic Right-of-use asset Operating Lease, Right-of-Use Asset Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Warrant liability, measurement input, term Warrants and Rights Outstanding, Term Number of shares called by warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Arrangement Duration Trading Arrangement Duration Number of additional shares authorized, percentage of common stock outstanding (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding Schedule of Other Noncurrent Assets Schedule of Other Assets, Noncurrent [Table Text Block] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Increase in number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant Related Party Related Party [Member] Principles of Consolidation Consolidation, Policy [Policy Text Block] Operating lease, base rent annual percentage increase (as a percent) Lessee, Operating Lease, Base Rent Annual Percentage Increase Lessee, Operating Lease, Base Rent Annual Percentage Increase Supplemental Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Other receivable Other Receivables, Gross, Current Operating lease, annual rent payment Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Available-for-sale securities Investment in convertible notes receivable Debt Securities, Available-for-Sale Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Notes Receivable, Two Notes Receivable, Two [Member] Notes Receivable, Two Adjustments to reconcile net loss to cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Notes Receivable Notes Receivable [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Payment for warrant liability Class Of Warrant Or Right, Payment For Liability Class Of Warrant Or Right, Payment For Liability Percentage of outstanding shares allowable as annual increase (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Title of Individual [Domain] Title of Individual [Domain] Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in capital Additional Paid in Capital Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Employee Stock Option Subsequent Employee Stock Option [Member] Subsequent Employee Stock Option [Member] Period in between reoccurring put option Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option Lease costs Lease, Cost, Current Lease, Cost, Current Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Fair value of underlying common stock (in dollars per share) Share Price Related Party [Axis] Related Party, Type [Axis] Ownership percentage limitation at election of purchaser (as a percent) Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Vesting of restricted stock units and related repurchases Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Reclassification of common stock warrants to liability Adjustments To Additional Paid in Capital, Decrease Related To Reclassification Adjustments To Additional Paid in Capital, Decrease Related To Reclassification Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Other Gain (Loss) on Disposition of Property Plant Equipment Share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Computers and software Computers and Software [Member] Computers and Software [Member] Provision for income taxes Income Tax Expense (Benefit) Accrued payroll-related expenses Employee-related Liabilities, Current Vesting [Axis] Vesting [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Ownership percentage limitation (as a percent) Class Of Warrant Or Right, Ownership Percentage Limitation Class Of Warrant Or Right, Ownership Percentage Limitation Issuance of common stock, net Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag License Agreement Intangible Assets Disclosure [Text Block] Legal Entity [Axis] Legal Entity [Axis] Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Assets Assets, Fair Value Disclosure [Abstract] Maximum number of shares per employee in purchase period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Pre-Funded Warrants And Accompanying Warrant Pre-Funded Warrants And Accompanying Warrant [Member] Pre-Funded Warrants And Accompanying Warrant Weighted-average diluted common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Operating expenses: Operating Expenses [Abstract] Company Selected Measure Amount Company Selected Measure Amount Period of no rental cost Lessee, Operating Sublease, Period Of No Rent Cost Lessee, Operating Sublease, Period Of No Rent Cost Biopharmaceutical Company Biopharmaceutical Company [Member] Biopharmaceutical Company Additional Paid-in- Capital Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Scientific equipment Equipment [Member] Vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent Events Subsequent Events [Text Block] Equity-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Other Other Prepaid Expense, Current Fair Value, Recurring Fair Value, Recurring [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Total operating expenses Operating Expenses Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Variable lease costs Variable Lease, Cost, Net Variable Lease, Cost, Net Number of subscription agreements entered into Number Of Subscription Agreements Entered Number Of Subscription Agreements Entered Non-PEO NEO Non-PEO NEO [Member] Operating lease, renewal term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] ESPP purchase price as a percentage of market price (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-average basic common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating loss Operating Income (Loss) Gross proceeds Proceeds From Issuance Of Common Stock And Warrants Proceeds From Issuance Of Common Stock And Warrants Revenue: Revenues [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exicure, Inc. 2017 Equity Incentive Plan Exicure, Inc. 2017 Equity Incentive Plan [Member] Exicure, Inc. 2017 Equity Incentive Plan [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Period One Share-Based Payment Arrangement, Tranche One [Member] EX-101.PRE 9 xcur-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
Jun. 10, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-39011  
Entity Registrant Name EXICURE, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-5333008  
Entity Address, Address Line One 2430 N. Halsted St.  
Entity Address, City or Town Chicago  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60614  
City Area Code (847)  
Local Phone Number 673-1700  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol XCUR  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   8,651,148
Entity Central Index Key 0001698530  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 366 $ 816
Other receivable 1 15
Prepaid expenses and other current assets 1,096 1,193
Total current assets 1,463 2,024
Property and equipment, net 47 54
Right-of-use asset 6,323 6,517
Other noncurrent assets 2,878 2,985
Total assets 10,711 11,580
Current liabilities:    
Accounts payable 1,825 1,631
Accrued expenses and other current liabilities 836 879
Total current liabilities 2,661 2,510
Lease liability, noncurrent 5,843 6,039
Total liabilities 8,504 8,549
Commitments and Contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, March 31, 2024 and December 31, 2023 0 0
Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 8,650,950 issued and outstanding, March 31, 2024; 8,650,753 issued and outstanding, December 31, 2023 1 1
Additional paid-in capital 192,598 192,593
Accumulated deficit (190,392) (189,563)
Total stockholders’ equity 2,207 3,031
Total liabilities and stockholders’ equity $ 10,711 $ 11,580
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 8,650,950 8,650,753
Common stock, shares outstanding (in shares) 8,650,950 8,650,753
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:    
Revenue $ 500,000 $ 0
Operating expenses:    
Research and development expense 0 1,423,000
General and administrative expense 1,336,000 3,116,000
Total operating expenses 1,336,000 4,539,000
Operating loss (836,000) (4,539,000)
Other income, net:    
Dividend income 4,000 17,000
Interest income 3,000 11,000
Other income, net 0 104,000
Total other income, net 7,000 132,000
Net loss before provision for income taxes (829,000) (4,407,000)
Provision for income taxes 0 0
Net loss $ (829,000) $ (4,407,000)
Basic loss per common share (in dollars per share) $ (0.10) $ (0.70)
Diluted loss per common share (in dollars per share) $ (0.10) $ (0.70)
Weighted-average basic common shares outstanding (in shares) 8,650,878 6,288,952
Weighted-average diluted common shares outstanding (in shares) 8,650,878 6,288,952
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in- Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   4,965,901    
Beginning balance at Dec. 31, 2022 $ 14,922 $ 0 $ 187,571 $ (172,649)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity-based compensation 308   308  
Reclassification of common stock warrants to liability (800)   (800)  
Vesting of restricted stock units and related repurchases (in shares)   5,561    
Vesting of restricted stock units and related repurchases (1) $ 1 (2)  
Issuance of common stock, net (in shares)   3,400,000    
Issuance of common stock, net 4,597   4,597  
Net loss (4,407)     (4,407)
Ending balance (in shares) at Mar. 31, 2023   8,371,462    
Ending balance at Mar. 31, 2023 $ 14,619 $ 1 191,674 (177,056)
Beginning balance (in shares) at Dec. 31, 2023 8,650,753 8,650,753    
Beginning balance at Dec. 31, 2023 $ 3,031 $ 1 192,593 (189,563)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity-based compensation 5   5  
Vesting of restricted stock units and related repurchases (in shares)   197    
Net loss $ (829)     (829)
Ending balance (in shares) at Mar. 31, 2024 8,650,950 8,650,950    
Ending balance at Mar. 31, 2024 $ 2,207 $ 1 $ 192,598 $ (190,392)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (829) $ (4,407)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 7 251
Equity-based compensation 5 308
Amortization of right-of-use asset 194 180
Other 0 (105)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 218 157
Other noncurrent assets 0 180
Accounts payable 194 91
Accrued expenses (43) 199
Other liabilities (196) (172)
Net cash used in operating activities (450) (3,318)
Cash flows from investing activities:    
Proceeds from sale of property and equipment 0 106
Net cash provided by investing activities 0 106
Cash flows from financing activities:    
Proceeds from common stock offering 0 5,440
Payment of common stock financing costs 0 (843)
Payments for minimum statutory tax withholding related to net share settlement of equity awards 0 (2)
Net cash provided by provided by financing activities 0 4,595
Net (decrease) increase in cash, cash equivalents, and restricted cash (450) 1,383
Cash, cash equivalents, and restricted cash - beginning of period 2,016 9,777
Cash, cash equivalents, and restricted cash - end of period 1,566 11,160
Non-cash investing activities:    
Reclassification of common stock warrants to liability $ 0 $ 800
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Statement of Cash Flows [Abstract]    
Cash and cash equivalents $ 366 $ 816
Restricted cash included in other noncurrent assets 1,200 1,200
Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows $ 1,566 $ 2,016
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Description of Business, Basis of Presentation and Going Concern
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Description of Business, Basis of Presentation and Going Concern Description of Business, Basis of Presentation and Going Concern
Description of Business
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. While the foregoing efforts are continuing with respect to the Company’s historical assets, the Company does not expect they will generate significant value for stockholders. Therefore, the Company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. The Company is exploring transactions in industries unrelated to its historical operations.
Throughout these unaudited condensed consolidated financial statements, the terms the “Company,” and “Exicure” refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company. Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc. 
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023, and for the three months ended March 31, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.
Unaudited Interim Financial Information
The accompanying interim condensed consolidated balance sheet as of March 31, 2024, the interim condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the interim condensed consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2024 and 2023, and the interim condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023, and the results of its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, or any other interim periods, or any future year or period. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on June 6, 2024.
Going Concern
At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.
The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the financial statements are issued. As of March 31, 2024, the Company expects to incur significant expenses and negative cash flows for the foreseeable future. As of March 31, 2024, the Company’s cash and cash equivalents were $366. Management believes that, given the Company’s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. Substantial additional financing will be needed by the Company to fund its operations.
Management believes that the Company’s existing cash and cash equivalents are insufficient to continue to fund its operating expenses and additional funding is needed in the very near term. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend the Company’s operating runway is limited. As a result, substantial additional financing will be needed by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.
The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Significant Accounting Policies Significant Accounting Policies
The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company’s Annual Report on Form 10-K (the “Annual Report”) for the year ended December 31, 2023 filed with the SEC on June 6, 2024. Since the date of those audited consolidated financial statements, there have been no material changes to the Company’s significant accounting policies.
Use of Estimates
The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Balance Sheet Information
 3 Months Ended
Mar. 31, 2024
Supplemental Balance Sheet Information [Abstract]  
Supplemental Balance Sheet Information Supplemental Balance Sheet Information
Prepaid expenses and other current assets
March 31, 2024December 31, 2023
Prepaid insurance$480 $508 
Prepaid franchise tax160 259 
Lease costs250 235 
Prepaid professional fees70 95 
Prepaid software 63 72 
Other73 24 
     Prepaid expenses and other current assets$1,096 $1,193 
Other noncurrent assets
March 31, 2024December 31, 2023
Restricted cash$1,200 $1,200 
Prepaid insurance1,678 1,785 
     Other noncurrent assets$2,878 $2,985 
Property and equipment, net
March 31, 2024December 31, 2023
Scientific equipment$246 $246 
Computers and software3 3 
Furniture and fixtures30 30 
Property and equipment, gross279 279 
Less: accumulated depreciation and amortization(232)(225)
Property and equipment, net$47 $54 
Depreciation and amortization expense was $7 and $251 for the three months ended March 31, 2024 and 2023, respectively.
Accrued expenses and other current liabilities
March 31, 2024December 31, 2023
Lease liability$650 $626 
Accrued payroll-related expenses43 71 
Accrued other expenses143 182 
     Accrued expenses and other current liabilities$836 $879 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Leases Leases
The Company’s lease arrangements at March 31, 2024 consist of (i) a lease for office space at its headquarters in Chicago, Illinois that commenced in July 2020 (the “Chicago Lease”) and (ii) a lease for office equipment (the “Office Equipment Lease”). The Chicago Lease and the Office Equipment Lease are classified as operating leases.
Chicago Lease
The Company has approximately thirty thousand square feet of office space in Chicago, Illinois. The original term (the “Original Term”) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the “Commencement Date”), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the “Extension Periods”) at the then prevailing effective market rental rate.
The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes were subject to certain abatements.
The following table summarizes lease costs in the Company’s unaudited condensed consolidated statement of operations:
Three Months Ended
March 31,
20242023
Operating lease costs$143 $326 
Variable lease costs120 332 
Short term lease costs11 — 
Total lease costs$274 $658 
The Company made cash payments for operating leases $0 and $646 during the three months ended March 31, 2024 and 2023, respectively. Amounts owed are included in accounts payable as of March 31, 2024. On June 11, 2024, the Company received a formal notice from its landlord indicating the landlord will draw on the restricted cash account designated for the lease as a result of past due rent for December 2023 through June 2024. This draw is within the terms and conditions of the lease and the related restricted cash account.
Sublease of Office Space
The Company entered into a sublease agreement with Cyclopure, Inc. (the “Subtenant”) to sublease approximately 57% of its office space pursuant to that certain sublease agreement (the “Sublease Agreement”), dated as of May 4, 2023. The term of the Sublease Agreement began on May 15, 2023 and ends on June 30, 2030, the expiration date of the Chicago Lease. The first three months under the Sublease Agreement are rent free. Beginning August 15, 2023, the Company began charging the Subtenant for 57% of the base rent under the Chicago Lease, and the subtenant is responsible for its pro rata share of operating expenses and taxes payable. In 2024, the Company does not receive payment from the Subtenant as the Subtenant pays the Company’s landlord directly.
The following table summarizes sublease receipts in the Company’s condensed consolidated statement of operations:
Three Months Ended
March 31,
20242023
Sublease amounts paid to landlord$173 $— 
Total$173 $— 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Investment in Convertible Notes Receivable
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Investment in Convertible Notes Receivable Investment in Convertible Notes Receivable
In May 2023, the Company entered into two subscription agreements to purchase non-guaranteed private placement convertible notes receivable (the “Notes Receivable”) for a subscription amount of $1 million each. The Notes Receivable mature in May 2026 and the yield to maturity is 4.5% per annum. The Company has the option to request that the issuer redeem part or the entire principal amount of the Notes Receivable on the first anniversary after the issue date and every three months thereafter before the maturity date. The conversion ratio will be one hundred percent (100%) of the Notes Receivable’s face value. The Company also has the ability to convert the debt into shares based on the number of shares computed by dividing the face value of each security by a calculated conversion price, which is subject to adjustment provisions, determined at the time of issuance. The securities may be converted from May 3, 2024, the first anniversary of the issue date of the first agreement, to April 15, 2026, one month prior to the maturity date to the second agreement. In March 2024, the Company notified the issuer of the Notes Receivable that it was exercising its redemption right with respect to the entire principal amount of the Notes Receivable after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of $2.090 million (representing the principal amount plus 4.5% per annum yield to the redemption date). The issuer has taken the position that the Notes Receivable are not redeemable until August 3, 2024 and August 16, 2024.
The Company’s debt securities are classified as AFS pursuant to Accounting Standards Codification (“ASC”) 320 - Investments - Debt Securities. AFS securities are recorded at fair value. As of March 31, 2024 and December 31, 2023, management does not believe these AFS investments are recoverable and recorded them at a fair value of $0.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stockholders' Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Preferred Stock
As of March 31, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.
Common Stock
As of March 31, 2024 and December 31, 2023, the Company had authorized 200,000,000 shares of common stock, par value $0.0001. As of March 31, 2024 and December 31, 2023, the Company had 8,650,950 shares and 8,650,753 shares issued and outstanding, respectively.
The holders of shares of the Company’s common stock are entitled to one vote per share on all matters to be voted upon by the Company’s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company’s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board of Directors (the “Board”) out of funds legally available for that purpose. In the event of the Company’s liquidation, dissolution or winding up, the holders of shares of the Company’s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company’s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company’s common stock. The outstanding shares of the Company’s common stock are fully paid and non-assessable.
September 2022 PIPE (Private Investment in Public Equity)
Securities Purchase Agreement
On September 26, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with CBI USA, Inc. (“CBI USA”), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of $1.60 per share. The private placement closed on February 24, 2023 (the “Closing Date”). The Company received gross proceeds of $5,440 from the September 2022 PIPE (or net proceeds of $4,597 after transaction expenses).
CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. (“DGP”). On June 23, 2023, DGP exercised its the option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on June 30, 2024.
The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any “group” of which it or they are a member with the right to designate directors to the Company’s board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on June 30, 2024.
September 2022 Registration Rights Agreement
In connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement with CBI USA (the “Registration Rights Agreement’). CBI USA assigned its rights under the Registration Rights Agreement to DGP when DGP acquired the 3,400,000 shares of Common Stock initially sold to CBI USA. Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the shares of Common Stock sold pursuant to the Securities Purchase Agreement, to use reasonable best efforts to cause such registration statement to become effective as promptly as practicable, and to keep such registration statement continuously effective until the earlier of (i) the date the shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction, or (ii) the date that is two (2) years following the Closing Date.
In the event the registration statement was not filed within 90 days following the Closing Date, subject to certain limited exceptions, the Company agreed to make payments as liquidated damages in an amount equal to 0.5% of the aggregate amount invested in the shares of Common Stock pursuant to the Securities Purchase Agreement per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. We have paid $27 to CBI USA and accrued $191 to DGP pursuant to this provision.
Registered Direct Offering
On December 16, 2021, the Company completed a securities purchase agreement (the “Purchase Agreement”) with certain institutional purchasers (the “Purchasers”) entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at-the-market consistent with the rules of Nasdaq (the “Registered Direct Offering”), (i) an aggregate of 433,553 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 718,981 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 576,261 shares of Common Stock (the “Warrants”). The combined purchase price of each share of Common Stock and accompanying Warrant is $9.9780 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is $9.9480 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.03). The per share exercise price for the Warrants is $8.1031, the closing bid price of the Company’s Common Stock on December 13, 2021 (and as adjusted for the reverse stock split referenced in Note 1). The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders’ equity within additional paid-in-capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were $11,478 and net proceeds after deducting the placement agent’s fees and other offering expenses paid or payable by the Company were $10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the “Registration Statement”).
Each Warrant is exercisable for one share of Common Stock at an exercise price of $8.1031 per share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.030 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder’s option upon issuance, 9.99%) of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares of Common Stock to the Warrant holder.
In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants.
Common Stock Warrants
Warrants to purchase 576,261 shares of common stock at a price of $8.1031 per share were acquired in the December 2021 registered-direct offering transaction. The warrants were classified as equity. As a result of the closing of the September 2022 PIPE, a warrant holder elected to exercise their option within 30 days of the closing of the September 2022 PIPE (February 24, 2023) to receive a cash payout for the outstanding warrants in the amount of the Black-Scholes value of each warrant as prescribed in the warrant agreement. The Company paid $800 to this warrant holder on June 23, 2023 and 526,151 were settled as a result. As of March 31, 2024, warrants to purchase 50,110 shares of common stock at a price of $8.1031 per share that were acquired in the December 2021 registered-direct offering transaction remain outstanding.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Equity-Based Compensation Equity-Based Compensation
2017 Equity Incentive Plan
On September 22, 2017, the Company’s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 194,750 shares of Exicure common stock, which includes 72,330 shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 122,793 that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the “2015 Plan”) and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 153,333 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the “Compensation Committee”). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2023, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 153,333 awards.         
As of March 31, 2024, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 455,765.
Awards granted under the 2017 Plan are contingent on the participants’ continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above.
Employee Stock Purchase Plan
The 2017 Employee Stock Purchase Plan (the “ESPP”) was adopted by the Board in September 2017 and approved by the Company’s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 250 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee’s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date.
The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 10,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2023, the number of shares of common stock available for issuance under the ESPP increased by 10,000 shares. As of March 31, 2024, there were 61,971 shares available for issuance under the ESPP.
Equity-based compensation expense is classified in the statements of operations as follows:
Three Months Ended
March 31,
20242023
Research and development expense$— $154 
General and administrative expense5 154 
$5 $308 

Unamortized equity-based compensation expense at March 31, 2024 was $27, which is expected to be amortized over a weighted-average period of 1.6 years.
The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The model also requires the input of highly subjective assumptions. No options were granted during the three months ended March 31, 2024. The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the three months ended March 31, 2023:
Three Months Ended
March 31,
2023
Expected term
5.8 to 5.8 years
Risk-free interest rate
3.83% to 3.83%; weighted avg. 3.83%
Expected volatility
101.0% to 101.0%; weighted avg. 101.0%
Forfeiture rate5 %
Expected dividend yield— %
The expected term is based upon the “simplified method” as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the “simplified method” until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. For stock options granted after December 31, 2021, the expected volatility is based on the volatility of shares of the Company. For stock options granted prior to January 1, 2022, the expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant.
The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2023 are summarized in the table below. No options were granted during the three months ended March 31, 2024.
Fair Value of Underlying Common StockExercise Price of Common Stock Option
Three months ended March 31, 2023
$1.58;
weighted avg. $1.58
$1.58;
weighted avg. $1.58

The weighted-average grant date fair value of common stock options granted in the three months ended March 31, 2023 was $1.26 per common stock option.
A summary of common stock option activity as of the periods indicated is as follows:
OptionsWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (years)Aggregate Intrinsic Value (thousands)
Outstanding - December 31, 202312,115 $4.28 5.4$— 
Granted— — 
Exercised— — 
Forfeited(416)5.51 
Outstanding - March 31, 202411,699 $5.51 5.1$— 
Exercisable - March 31, 202411,699 $5.51 5.1$— 
Vested and Expected to Vest -
March 31, 2024		11,699 $5.51 5.1$— 
A summary of restricted stock unit activity of the periods indicated is as follows:
Restricted Stock UnitsWeighted-Average Grant Date Fair Value
Unvested balance - December 31, 20233,043 $10.41 
Granted— — 
Vested(296)18.47 
Forfeited(417)3.45 
Unvested balance - March 31, 20242,330 $13.03 
The grant date fair value of restricted stock units is based on the Company’s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company’s common stock. Restricted stock units generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesThe Company incurred a pretax loss in each of the three months ended March 31, 2024 and 2023, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended. The effective tax rate is 0% in each of the three months ended March 31, 2024 and 2023 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Loss Per Common Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Loss Per Common Share Loss Per Common Share
Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the three months ended March 31, 2024 and 2023.
The following is the computation of loss per common share for the three months ended March 31, 2024 and 2023:
Three Months Ended
March 31,
20242023
Net loss$(829)$(4,407)
Weighted-average basic and diluted common shares outstanding8,650,878 6,288,952 
Loss per share - basic and diluted$(0.10)$(0.70)
The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period:
As of March 31,
20242023
Options to purchase common stock11,699 203,406 
Restricted stock units2,330 8,784 
Performance stock units— 97,643 
Warrants to purchase common stock50,110 576,261 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
Assets measured at fair value on a recurring basis as of March 31, 2024 are as follows:
TotalLevel 1Level 2Level 3
Assets
Cash equivalents:
Money market funds$273 $273 $— $— 
Short-term investments:
Investment in convertible notes receivable— — — — 
Total financial assets$273 $273 $— $— 
    

Assets measured at fair value on a recurring basis as of December 31, 2023 are as follows:
TotalLevel 1Level 2Level 3
Assets
Cash equivalents:
Money market funds$1,629 $1,629 $— $— 
Short-term investments:
Investment in convertible notes receivable— — — — 
Total financial assets$1,629 $1,629 $— $— 
The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company uses the market approach and Level 3 inputs to value its liabilities. There were no liabilities measured at fair value on a recurring basis as of as of December 31, 2023 nor March 31, 2024.
There were no transfers between Level 1, 2, or 3, during the three months ended March 31, 2024, and 2023. Both observable and unobservable in puts were used to determine fair value of the positions that the Company classified within the Level 3 category. Unrealized gains and losses associated within the Level 3 category include changes in fair value that were attributable to both observable and unobservable inputs.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitment and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Proceedings
On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663. On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti & Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. The parties filed a joint status report noting the mediation efforts taken by the parties. The report also proposes a litigation schedule going forward, which the Court adopted: plaintiff's third amended complaint is due on or before June 28, 2024, and any motion to dismiss is due on or before August 27, 2024, with response due on or before October 8, 2024 and any reply due on or before November 5, 2024. Accordingly, the status hearing set for May 22, 2024 is reset to July 23, 2024.
On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Dr. Giljohann and Mr. Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned Stourbridge Investments LLC v. Exicure, Inc. et al., Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints (collectively, the “Derivative Complaints”) allege that the defendants caused the Company to issue false and/or misleading statements in the proxy statement for its 2021 Annual Meeting of Stockholders regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders.
On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision.
On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee’s separation from the Company. The parties will proceed with paper discovery and an in-person settlement conference is scheduled for June 26, 2024.
Northwestern University License Agreements
On December 12, 2011, (1) AuraSense, LLC, the Company’s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC’s 2009 license agreement with Northwestern University (“NU”) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the “assigned field”); (2) in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3) in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company’s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee’s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company. In August 2015, the Company entered into a restated license agreement with NU (the “Restated License Agreement”). In February 2016, the Company obtained exclusive license as to NU’s rights in certain SNA technology it jointly owns with NU (the “Co-owned Technology License”). The Company’s license to NU’s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. The Company’s rights and obligations in the Co-owned Technology License agreement is substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as “the Northwestern University License Agreements”). As of March 31, 2024, the Company has paid to NU an aggregate of $11,567 in consideration of each of the obligations described above.
On August 3, 2023, the company received a notice letter (the “Letter”) from counsel for NU alleging the Company breached the Northwestern University License Agreements. The Letter alleges that a lack of development required under the Northwestern University License Agreements is a breach. The Northwestern University License Agreements were subsequently terminated on September 10, 2023 and October 3, 2023, respectively.
Leases
Refer to Note 4, Leases, for a discussion of the commitments associated with the Company’s lease agreements.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related-Party Transactions
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related-Party Transactions Related-Party Transactions
Pursuant to a Consulting Agreement, effective as of September 25, 2022, between the Company and Alta Companies LTD (“Alta”), the Company paid Alta $218 on February 27, 2023 for a consulting fee earned as a result of the September 2022 PIPE closing. Paul Kang, a director of the Company since February 2023 and the CEO of the Company since August 2023, is the President of Alta.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
License Agreement
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
License Agreement License Agreement
On February 5, 2024, the Company entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis with a private clinical stage biopharmaceutical company. Under the terms of the agreement, this biopharmaceutical company will receive an exclusive license in the field of hepatitis to all of the Company’s relevant patents. An initial payment of $500 was paid to the Company after the execution of this agreement. This payment was recognized as revenue in accordance with ASC 606, Revenue from Contracts with Customers. The Company will also be entitled to modest royalties on future net sales on all licensed technology during the term of the licensed patents. The Company will be responsible for, and make all decisions concerning, the
preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On May 3, 2024, the Company executed a promissory note (“Note”) and subsequently received a loan in the amount of $300 from an individual investor. All principal and accrued interest will be due and payable on the earlier of (i) the 1st anniversary of the date of this Note or (ii) upon an event of default, at that time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this Note at 6.0% and is payable at maturity.
On June 3, 2024, the Company executed another promissory note (“DGP Note”) and subsequently received a loan in the amount of $700 from DGP, a related party. All principal and accrued interest will be due and payable on the earlier of (i) the ten-month anniversary of the date of this DGP Note or (ii) upon an event of default, at that time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this DGP Note at 6.0% and is payable at maturity.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net loss $ (829) $ (4,407)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023, and for the three months ended March 31, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended.
Principles of Consolidation
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.
Loss Per Common Share Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Balance Sheet Information (Tables)
 3 Months Ended
Mar. 31, 2024
Supplemental Balance Sheet Information [Abstract]  
Schedule of Prepaid and Other Current Assets
Prepaid expenses and other current assets
March 31, 2024December 31, 2023
Prepaid insurance$480 $508 
Prepaid franchise tax160 259 
Lease costs250 235 
Prepaid professional fees70 95 
Prepaid software 63 72 
Other73 24 
     Prepaid expenses and other current assets$1,096 $1,193 
Schedule of Other Noncurrent Assets
Other noncurrent assets
March 31, 2024December 31, 2023
Restricted cash$1,200 $1,200 
Prepaid insurance1,678 1,785 
     Other noncurrent assets$2,878 $2,985 
Schedule of Property and Equipment, Net
Property and equipment, net
March 31, 2024December 31, 2023
Scientific equipment$246 $246 
Computers and software3 3 
Furniture and fixtures30 30 
Property and equipment, gross279 279 
Less: accumulated depreciation and amortization(232)(225)
Property and equipment, net$47 $54 
Schedule of Accrued expenses and other current liabilities
Accrued expenses and other current liabilities
March 31, 2024December 31, 2023
Lease liability$650 $626 
Accrued payroll-related expenses43 71 
Accrued other expenses143 182 
     Accrued expenses and other current liabilities$836 $879 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Lease Costs
The following table summarizes lease costs in the Company’s unaudited condensed consolidated statement of operations:
Three Months Ended
March 31,
20242023
Operating lease costs$143 $326 
Variable lease costs120 332 
Short term lease costs11 — 
Total lease costs$274 $658 
The following table summarizes sublease receipts in the Company’s condensed consolidated statement of operations:
Three Months Ended
March 31,
20242023
Sublease amounts paid to landlord$173 $— 
Total$173 $— 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Equity-Based Compensation Expense Classification in Statement of Operations
Equity-based compensation expense is classified in the statements of operations as follows:
Three Months Ended
March 31,
20242023
Research and development expense$— $154 
General and administrative expense5 154 
$5 $308 
Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the three months ended March 31, 2023:
Three Months Ended
March 31,
2023
Expected term
5.8 to 5.8 years
Risk-free interest rate
3.83% to 3.83%; weighted avg. 3.83%
Expected volatility
101.0% to 101.0%; weighted avg. 101.0%
Forfeiture rate5 %
Expected dividend yield— %
The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2023 are summarized in the table below. No options were granted during the three months ended March 31, 2024.
Fair Value of Underlying Common StockExercise Price of Common Stock Option
Three months ended March 31, 2023
$1.58;
weighted avg. $1.58
$1.58;
weighted avg. $1.58
Schedule of Common Stock Option Activity
A summary of common stock option activity as of the periods indicated is as follows:
OptionsWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term (years)Aggregate Intrinsic Value (thousands)
Outstanding - December 31, 202312,115 $4.28 5.4$— 
Granted— — 
Exercised— — 
Forfeited(416)5.51 
Outstanding - March 31, 202411,699 $5.51 5.1$— 
Exercisable - March 31, 202411,699 $5.51 5.1$— 
Vested and Expected to Vest -
March 31, 2024		11,699 $5.51 5.1$— 
Schedule of Restricted Stock Unit Awards Activity
A summary of restricted stock unit activity of the periods indicated is as follows:
Restricted Stock UnitsWeighted-Average Grant Date Fair Value
Unvested balance - December 31, 20233,043 $10.41 
Granted— — 
Vested(296)18.47 
Forfeited(417)3.45 
Unvested balance - March 31, 20242,330 $13.03 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Loss Per Common Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Computation of Loss per Common Share
The following is the computation of loss per common share for the three months ended March 31, 2024 and 2023:
Three Months Ended
March 31,
20242023
Net loss$(829)$(4,407)
Weighted-average basic and diluted common shares outstanding8,650,878 6,288,952 
Loss per share - basic and diluted$(0.10)$(0.70)
Schedule of Antidilutive Securities
The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period:
As of March 31,
20242023
Options to purchase common stock11,699 203,406 
Restricted stock units2,330 8,784 
Performance stock units— 97,643 
Warrants to purchase common stock50,110 576,261 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Assets measured at fair value on a recurring basis as of March 31, 2024 are as follows:
TotalLevel 1Level 2Level 3
Assets
Cash equivalents:
Money market funds$273 $273 $— $— 
Short-term investments:
Investment in convertible notes receivable— — — — 
Total financial assets$273 $273 $— $— 
    

Assets measured at fair value on a recurring basis as of December 31, 2023 are as follows:
TotalLevel 1Level 2Level 3
Assets
Cash equivalents:
Money market funds$1,629 $1,629 $— $— 
Short-term investments:
Investment in convertible notes receivable— — — — 
Total financial assets$1,629 $1,629 $— $— 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Description of Business, Basis of Presentation and Going Concern (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Cash and cash equivalents $ 366 $ 816
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Supplemental Balance Sheet Information [Abstract]    
Prepaid insurance $ 480 $ 508
Prepaid franchise tax 160 259
Lease costs 250 235
Prepaid professional fees 70 95
Prepaid software 63 72
Other 73 24
Prepaid expenses and other current assets $ 1,096 $ 1,193
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Supplemental Balance Sheet Information [Abstract]    
Restricted cash $ 1,200 $ 1,200
Prepaid insurance 1,678 1,785
Other noncurrent assets $ 2,878 $ 2,985
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 279 $ 279
Less: accumulated depreciation and amortization (232) (225)
Property and equipment, net 47 54
Scientific equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 246 246
Computers and software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3 3
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 30 $ 30
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Balance Sheet Information - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Supplemental Balance Sheet Information [Abstract]    
Depreciation and amortization $ 7 $ 251
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Supplemental Balance Sheet Information [Abstract]    
Lease liability $ 650 $ 626
Accrued payroll-related expenses 43 71
Accrued other expenses 143 182
Accrued expenses and other current liabilities $ 836 $ 879
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Narrative (Details)
ft² in Thousands, $ in Thousands
 3 Months Ended
May 04, 2023
Jul. 01, 2020
USD ($)
ft²
extension_period
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Lessee, Lease, Description [Line Items]        
Operating lease, cash payments     $ 0 $ 646
Chicago        
Lessee, Lease, Description [Line Items]        
Operating lease area | ft²   30    
Operating lease, contract term   10 years    
Operating lease, number of extensions | extension_period   2    
Operating lease, renewal term   5 years    
Operating lease, annual rent payment   $ 1,113    
Operating lease, base rent annual percentage increase (as a percent)   3.00%    
Operating lease, estimated rental payment over lease term   $ 12,761    
Sublease percentage of office space subtenant (as a percent) 57.00%      
Period of no rental cost 3 months      
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Lease Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Leases [Abstract]    
Operating lease costs $ 143 $ 326
Variable lease costs 120 332
Short term lease costs 11 0
Total lease costs $ 274 $ 658
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Sublease Receipts (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Leases [Abstract]    
Sublease amounts paid to landlord $ 173 $ 0
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Investment in Convertible Notes Receivable - Narrative (Details)
 1 Months Ended
Mar. 31, 2024
USD ($)
May 31, 2023
USD ($)
agreement
Dec. 31, 2023
USD ($)
Debt Securities, Available-for-sale [Line Items]      
Available-for-sale securities $ 0   $ 0
Notes Receivable      
Debt Securities, Available-for-sale [Line Items]      
Number of subscription agreements entered into | agreement   2  
Stated yield 4.50% 4.50%  
Period in between reoccurring put option   3 months  
Face value conversion percentage   100.00%  
Proceeds from sale or maturity of available-for-sale securities $ 2,090,000.00    
Notes Receivable, One      
Debt Securities, Available-for-sale [Line Items]      
Available-for-sale securities   $ 1,000,000  
Notes Receivable, Two      
Debt Securities, Available-for-sale [Line Items]      
Available-for-sale securities   $ 1,000,000  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stockholders' Equity - Preferred and Common Stock (Details)
Mar. 31, 2024
vote
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
Equity [Abstract]    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Common stock, shares issued (in shares) 8,650,950 8,650,753
Common stock, shares outstanding (in shares) 8,650,950 8,650,753
Common stock, voting rights for each share | vote 1  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stockholders' Equity - Securities Purchase Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Jun. 23, 2023
Feb. 24, 2023
Sep. 26, 2022
Dec. 16, 2021
Feb. 29, 2024
Mar. 31, 2024
Dec. 31, 2023
Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]                
Registration rights agreement, required filing term     90 days          
Registration rights agreement, liquidation damages payable as a percent of amount invested, if filed late (as a percent)     0.50%          
Registration rights agreement, liquidation damages payable if filed late, measurement term     30 days          
Common stock, par value (in dollars per share)           $ 0.0001 $ 0.0001  
Exercise price (in dollars per share)           $ 8.1031   $ 8.1031
Warrant liability, measurement input, term       5 years        
Gross proceeds       $ 11,478        
Net proceeds       $ 10,226        
Ownership percentage limitation (as a percent)       4.99%        
Ownership percentage limitation at election of purchaser (as a percent)       9.99%        
DGP Co. Ltd                
Subsidiary, Sale of Stock [Line Items]                
Pro rata accrual           $ 191    
CBI USA, Inc                
Subsidiary, Sale of Stock [Line Items]                
Pro rata payment           $ 27    
Pre-Funded Warrants                
Subsidiary, Sale of Stock [Line Items]                
Warrants issued in sale of stock (in shares)       718,981        
Exercise price (in dollars per share)       $ 0.030        
Number of shares exercisable for each warrant (in shares)       1        
Warrant                
Subsidiary, Sale of Stock [Line Items]                
Warrants issued in sale of stock (in shares)       576,261        
Exercise price (in dollars per share)       $ 8.1031        
Number of shares exercisable for each warrant (in shares)       1        
Common Stock And Accompanying Warrant                
Subsidiary, Sale of Stock [Line Items]                
Purchase price (in dollars per share)       $ 9.9780        
Pre-Funded Warrants And Accompanying Warrant                
Subsidiary, Sale of Stock [Line Items]                
Purchase price (in dollars per share)       $ 9.9480        
Common Stock                
Subsidiary, Sale of Stock [Line Items]                
Number of shares issued in transaction (in shares)       433,553        
Common stock, par value (in dollars per share)       $ 0.0001        
Private Placement                
Subsidiary, Sale of Stock [Line Items]                
Number of shares issued in transaction (in shares)     3,400,000          
Sales price of shares issued in transaction (in dollars per share)     $ 1.60          
Consideration received, gross   $ 5,440            
Consideration for stock transaction   $ 4,597            
Private Placement | CBI USA & DGP Co. Ltd                
Subsidiary, Sale of Stock [Line Items]                
Percentage of ownership after transaction (as a percent)           45.00%    
Third Party Sale of Company Stock | CBI USA, Inc | DGP Co. Ltd                
Subsidiary, Sale of Stock [Line Items]                
Number of shares issued in transaction (in shares) 3,400,000              
Third Party Sale of Company Stock | DGP Co. Ltd | Third Party                
Subsidiary, Sale of Stock [Line Items]                
Number of shares issued in transaction (in shares)         340,000      
Percentage of shares subsequently sold at closing         10.00%      
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stockholders' Equity - Common Stock Warrants (Details) - USD ($)
$ / shares in Units, $ in Thousands
Jun. 23, 2023
Mar. 31, 2024
Dec. 31, 2021
Equity [Abstract]      
Number of shares called by warrants (in shares)   50,110 576,261
Exercise price (in dollars per share)   $ 8.1031 $ 8.1031
Payment for warrant liability $ 800    
Warrants settled (in shares) 526,151    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Jan. 01, 2023
Sep. 30, 2017
Mar. 31, 2024
Mar. 31, 2023
Sep. 22, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Compensation cost not yet recognized     $ 27    
Compensation expense recognition period     1 year 7 months 6 days    
Granted (in shares)     0    
Weighted-average grant date fair value (in dollars per share)       $ 1.26  
Employee Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)     61,971    
Maximum ESPP contribution rate as a percentage of compensation (as a percent)   15.00%      
Maximum number of shares per employee in purchase period (in shares)   250      
Maximum contribution amount   $ 25      
ESPP purchase price as a percentage of market price (as a percent)   85.00%      
Number of additional shares allowable annually under the plan (in shares)   10,000      
Percentage of outstanding shares allowable as annual increase (as a percent)   0.30%      
Increase in number of shares available for grant (in shares) 10,000        
Restricted stock units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period     4 years    
Number of shares issued for each vested restricted stock unit (in shares)     1    
Exicure, Inc. 2017 Equity Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares authorized (in shares)         194,750
Number of shares available for grant (in shares)     455,765   72,330
Number of additional shares authorized, potential maximum additional shares (in shares)     153,333    
Number of additional shares authorized, percentage of common stock outstanding (as a percent)     5.00%    
Exicure, Inc. 2017 Equity Incentive Plan | Share-based Payment Arrangement, Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares) 153,333        
Expiration period     10 years    
Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Monthly vesting percentage (as a percent)     2.08%    
Vesting period     48 months    
Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | Non-employee Director          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Monthly vesting percentage (as a percent)     2.78%    
Vesting period     36 months    
Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | Period One          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage (as a percent)     25.00%    
Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Monthly vesting percentage (as a percent)     2.08%    
Vesting period     48 months    
Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option | Non-employee Director          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Monthly vesting percentage (as a percent)     8.33%    
Vesting period     12 months    
Exicure OpCo 2015 Equity Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares)         122,793
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 5 $ 308
Research and development expense    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 0 154
General and administrative expense    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 5 $ 154
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details)
 3 Months Ended
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Risk-free interest rate, minimum 3.83%
Risk-free interest rate, maximum 3.83%
Expected volatility, minimum 101.00%
Expected volatility, maximum 101.00%
Expected volatility 101.00%
Forfeiture rate 5.00%
Expected dividend yield 0.00%
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected term 5 years 9 months 18 days
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected term 5 years 9 months 18 days
Weighted Average  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Risk-free interest rate 3.83%
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)
Mar. 31, 2023
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Fair value of underlying common stock (in dollars per share) $ 1.58
Exercise price of common stock option (in dollars per share) 1.58
Weighted Average  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Fair value of underlying common stock (in dollars per share) 1.58
Exercise price of common stock option (in dollars per share) $ 1.58
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Options    
Shares outstanding, beginning period (in shares) 12,115  
Granted (in shares) 0  
Exercise (in shares) 0  
Forfeited (in shares) (416)  
Shares outstanding, ending period (in shares) 11,699 12,115
Exercisable (in shares) 11,699  
Vested and expected to vest (in shares) 11,699  
Weighted-Average Exercise Price    
Outstanding beginning balance (in dollars per share) $ 4.28  
Granted (in dollars per share) 0  
Exercised (in dollars per share) 0  
Forfeited (in dollars per share) 5.51  
Outstanding ending balance (in dollars per share) 5.51 $ 4.28
Exercisable, weighted-average exercise price (in dollars per share) 5.51  
Vested and expected to vest, weighted-average exercise price (in dollars per share) $ 5.51  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]    
Weighted-Average Remaining Contractual Term (years) 5 years 1 month 6 days 5 years 4 months 24 days
Exercisable, weighted-average remaining contractual term 5 years 1 month 6 days  
Vested and expected to vest, weighted average remaining contractual term 5 years 1 month 6 days  
Aggregate Intrinsic Value (thousands) $ 0 $ 0
Exercisable, aggregate intrinsic value 0  
Vested and expected to vest, aggregate intrinsic value $ 0  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) - Restricted stock units
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Restricted Stock Units  
Unvested balance - beginning of period (in shares) | shares 3,043
Granted (in shares) | shares 0
Vested (in shares) | shares (296)
Forfeited (in shares) | shares (417)
Unvested balance - end of period (in shares) | shares 2,330
Weighted-Average Grant Date Fair Value  
Unvested balance - beginning of period (in dollars per share) | $ / shares $ 10.41
Granted (in dollars per share) | $ / shares 0
Vested (in dollars per share) | $ / shares 18.47
Forfeited (in dollars per share) | $ / shares 3.45
Unvested balance - end of period (in dollars per share) | $ / shares $ 13.03
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income Taxes - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Provision for income taxes $ 0 $ 0
Effective tax rate (as a percent) 0.00% 0.00%
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Loss Per Common Share - Schedule of Computation of loss per common share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net loss $ (829) $ (4,407)
Weighted-average basic common shares outstanding (in shares) 8,650,878 6,288,952
Weighted-average diluted common shares outstanding (in shares) 8,650,878 6,288,952
Loss per share - basic (in dollars per share) $ (0.10) $ (0.70)
Loss per share - diluted (in dollars per share) $ (0.10) $ (0.70)
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Loss Per Common Share - Schedule of Antidilutive Securities (Details) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) 11,699 203,406
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) 2,330 8,784
Performance stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) 0 97,643
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) 50,110 576,261
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Assets    
Investment in convertible notes receivable $ 0 $ 0
Fair Value, Recurring    
Assets    
Total financial assets 273,000 1,629,000
Fair Value, Recurring | Notes Receivable    
Assets    
Investment in convertible notes receivable 0 0
Fair Value, Recurring | Level 1    
Assets    
Total financial assets 273,000 1,629,000
Fair Value, Recurring | Level 1 | Notes Receivable    
Assets    
Investment in convertible notes receivable 0 0
Fair Value, Recurring | Level 2    
Assets    
Total financial assets 0 0
Fair Value, Recurring | Level 2 | Notes Receivable    
Assets    
Investment in convertible notes receivable 0 0
Fair Value, Recurring | Level 3    
Assets    
Total financial assets 0 0
Fair Value, Recurring | Level 3 | Notes Receivable    
Assets    
Investment in convertible notes receivable 0 0
Money market funds | Fair Value, Recurring    
Assets    
Cash equivalents: 273,000 1,629,000
Money market funds | Fair Value, Recurring | Level 1    
Assets    
Cash equivalents: 273,000 1,629,000
Money market funds | Fair Value, Recurring | Level 2    
Assets    
Cash equivalents: 0 0
Money market funds | Fair Value, Recurring | Level 3    
Assets    
Cash equivalents: $ 0 $ 0
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitment and Contingencies - Narrative (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Aggregate consideration paid to NU for agreement obligations $ 11,567
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related-Party Transactions - Narrative (Details)
$ in Thousands
Feb. 27, 2023
USD ($)
Related Party  
Related Party Transaction [Line Items]  
Amount of transaction $ 218
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
License Agreement (Details)
$ in Thousands
Feb. 05, 2024
USD ($)
Biopharmaceutical Company  
Finite-Lived Intangible Assets [Line Items]  
Proceeds from patent license agreement $ 500
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Subsequent Events (Details) - Subsequent Event - Promissory Note - USD ($)
Jun. 03, 2024
May 03, 2024
Subsequent Event [Line Items]    
Debt instrument, face amount   $ 300,000
Interest rate   6.00%
DGP Co. Ltd | Related Party    
Subsequent Event [Line Items]    
Debt instrument, face amount $ 700,000  
Interest rate 6.00%  
Debt term 10 months  
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 125 258 1 false 50 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.exicuretx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY Sheet http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY Statements 5 false false R6.htm 0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 0000008 - Disclosure - Description of Business, Basis of Presentation and Going Concern Sheet http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern Description of Business, Basis of Presentation and Going Concern Notes 8 false false R9.htm 0000009 - Disclosure - Significant Accounting Policies Sheet http://www.exicuretx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 10 false false R11.htm 0000011 - Disclosure - Leases Sheet http://www.exicuretx.com/role/Leases Leases Notes 11 false false R12.htm 0000012 - Disclosure - Investment in Convertible Notes Receivable Notes http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivable Investment in Convertible Notes Receivable Notes 12 false false R13.htm 0000013 - Disclosure - Stockholders' Equity Sheet http://www.exicuretx.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 0000014 - Disclosure - Equity-Based Compensation Sheet http://www.exicuretx.com/role/EquityBasedCompensation Equity-Based Compensation Notes 14 false false R15.htm 0000015 - Disclosure - Income Taxes Sheet http://www.exicuretx.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 0000016 - Disclosure - Loss Per Common Share Sheet http://www.exicuretx.com/role/LossPerCommonShare Loss Per Common Share Notes 16 false false R17.htm 0000017 - Disclosure - Fair Value Measurements Sheet http://www.exicuretx.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 0000018 - Disclosure - Commitment and Contingencies Sheet http://www.exicuretx.com/role/CommitmentandContingencies Commitment and Contingencies Notes 18 false false R19.htm 0000019 - Disclosure - Related-Party Transactions Sheet http://www.exicuretx.com/role/RelatedPartyTransactions Related-Party Transactions Notes 19 false false R20.htm 0000020 - Disclosure - License Agreement Sheet http://www.exicuretx.com/role/LicenseAgreement License Agreement Notes 20 false false R21.htm 0000021 - Disclosure - Subsequent Events Sheet http://www.exicuretx.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.exicuretx.com/role/SignificantAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.exicuretx.com/role/SupplementalBalanceSheetInformation 25 false false R26.htm 9954473 - Disclosure - Leases (Tables) Sheet http://www.exicuretx.com/role/LeasesTables Leases (Tables) Tables http://www.exicuretx.com/role/Leases 26 false false R27.htm 9954474 - Disclosure - Equity-Based Compensation (Tables) Sheet http://www.exicuretx.com/role/EquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://www.exicuretx.com/role/EquityBasedCompensation 27 false false R28.htm 9954475 - Disclosure - Loss Per Common Share (Tables) Sheet http://www.exicuretx.com/role/LossPerCommonShareTables Loss Per Common Share (Tables) Tables http://www.exicuretx.com/role/LossPerCommonShare 28 false false R29.htm 9954476 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.exicuretx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.exicuretx.com/role/FairValueMeasurements 29 false false R30.htm 9954477 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Details) Sheet http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetails Description of Business, Basis of Presentation and Going Concern (Details) Details http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern 30 false false R31.htm 9954478 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) Details 31 false false R32.htm 9954479 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) Details 32 false false R33.htm 9954480 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) Details 33 false false R34.htm 9954481 - Disclosure - Supplemental Balance Sheet Information - Narrative (Details) Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformationNarrativeDetails Supplemental Balance Sheet Information - Narrative (Details) Details 34 false false R35.htm 9954482 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) Sheet http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) Details 35 false false R36.htm 9954483 - Disclosure - Leases - Narrative (Details) Sheet http://www.exicuretx.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 36 false false R37.htm 9954484 - Disclosure - Leases - Lease Costs (Details) Sheet http://www.exicuretx.com/role/LeasesLeaseCostsDetails Leases - Lease Costs (Details) Details 37 false false R38.htm 9954485 - Disclosure - Leases - Sublease Receipts (Details) Sheet http://www.exicuretx.com/role/LeasesSubleaseReceiptsDetails Leases - Sublease Receipts (Details) Details 38 false false R39.htm 9954486 - Disclosure - Investment in Convertible Notes Receivable - Narrative (Details) Notes http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails Investment in Convertible Notes Receivable - Narrative (Details) Details 39 false false R40.htm 9954487 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Details) Sheet http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails Stockholders' Equity - Preferred and Common Stock (Details) Details 40 false false R41.htm 9954488 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details) Sheet http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails Stockholders' Equity - Securities Purchase Agreement (Details) Details 41 false false R42.htm 9954489 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details) Sheet http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails Stockholders' Equity - Common Stock Warrants (Details) Details 42 false false R43.htm 9954490 - Disclosure - Equity-Based Compensation - Narrative (Details) Sheet http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails Equity-Based Compensation - Narrative (Details) Details 43 false false R44.htm 9954491 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) Sheet http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) Details 44 false false R45.htm 9954492 - Disclosure - Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details) Sheet http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details) Details 45 false false R46.htm 9954493 - Disclosure - Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) Sheet http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) Details 46 false false R47.htm 9954494 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) Sheet http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) Details 47 false false R48.htm 9954495 - Disclosure - Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) Sheet http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) Details 48 false false R49.htm 9954496 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 49 false false R50.htm 9954497 - Disclosure - Loss Per Common Share - Schedule of Computation of loss per common share (Details) Sheet http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails Loss Per Common Share - Schedule of Computation of loss per common share (Details) Details 50 false false R51.htm 9954498 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities (Details) Sheet http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails Loss Per Common Share - Schedule of Antidilutive Securities (Details) Details 51 false false R52.htm 9954499 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 52 false false R53.htm 9954500 - Disclosure - Commitment and Contingencies - Narrative (Details) Sheet http://www.exicuretx.com/role/CommitmentandContingenciesNarrativeDetails Commitment and Contingencies - Narrative (Details) Details 53 false false R54.htm 9954501 - Disclosure - Related-Party Transactions - Narrative (Details) Sheet http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails Related-Party Transactions - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - License Agreement (Details) Sheet http://www.exicuretx.com/role/LicenseAgreementDetails License Agreement (Details) Details http://www.exicuretx.com/role/LicenseAgreement 55 false false R56.htm 9954503 - Disclosure - Subsequent Events (Details) Sheet http://www.exicuretx.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.exicuretx.com/role/SubsequentEvents 56 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage - xcur-20240331.htm 4 xcur-20240331.htm xcur-20240331.xsd xcur-20240331_cal.xml xcur-20240331_def.xml xcur-20240331_lab.xml xcur-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xcur-20240331.htm": { "nsprefix": "xcur", "nsuri": "http://www.exicuretx.com/20240331", "dts": { "inline": { "local": [ "xcur-20240331.htm" ] }, "schema": { "local": [ "xcur-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "xcur-20240331_cal.xml" ] }, "definitionLink": { "local": [ "xcur-20240331_def.xml" ] }, "labelLink": { "local": [ "xcur-20240331_lab.xml" ] }, "presentationLink": { "local": [ "xcur-20240331_pre.xml" ] } }, "keyStandard": 212, "keyCustom": 46, "axisStandard": 22, "axisCustom": 0, "memberStandard": 24, "memberCustom": 20, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 5, "http://www.exicuretx.com/20240331": 4 }, "contextCount": 125, "entityCount": 1, "segmentCount": 50, "elementCount": 493, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 414, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.exicuretx.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherReceivablesGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R3": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "longName": "0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R7": { "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical", "longName": "0000007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R8": { "role": "http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern", "longName": "0000008 - Disclosure - Description of Business, Basis of Presentation and Going Concern", "shortName": "Description of Business, Basis of Presentation and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.exicuretx.com/role/SignificantAccountingPolicies", "longName": "0000009 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation", "longName": "0000010 - Disclosure - Supplemental Balance Sheet Information", "shortName": "Supplemental Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.exicuretx.com/role/Leases", "longName": "0000011 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivable", "longName": "0000012 - Disclosure - Investment in Convertible Notes Receivable", "shortName": "Investment in Convertible Notes Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.exicuretx.com/role/StockholdersEquity", "longName": "0000013 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.exicuretx.com/role/EquityBasedCompensation", "longName": "0000014 - Disclosure - Equity-Based Compensation", "shortName": "Equity-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.exicuretx.com/role/IncomeTaxes", "longName": "0000015 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.exicuretx.com/role/LossPerCommonShare", "longName": "0000016 - Disclosure - Loss Per Common Share", "shortName": "Loss Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.exicuretx.com/role/FairValueMeasurements", "longName": "0000017 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.exicuretx.com/role/CommitmentandContingencies", "longName": "0000018 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.exicuretx.com/role/RelatedPartyTransactions", "longName": "0000019 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.exicuretx.com/role/LicenseAgreement", "longName": "0000020 - Disclosure - License Agreement", "shortName": "License Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.exicuretx.com/role/SubsequentEvents", "longName": "0000021 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables", "longName": "9954472 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.exicuretx.com/role/LeasesTables", "longName": "9954473 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationTables", "longName": "9954474 - Disclosure - Equity-Based Compensation (Tables)", "shortName": "Equity-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.exicuretx.com/role/LossPerCommonShareTables", "longName": "9954475 - Disclosure - Loss Per Common Share (Tables)", "shortName": "Loss Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.exicuretx.com/role/FairValueMeasurementsTables", "longName": "9954476 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetails", "longName": "9954477 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Details)", "shortName": "Description of Business, Basis of Presentation and Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails", "longName": "9954478 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidInsurance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails", "longName": "9954479 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails", "longName": "9954480 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationNarrativeDetails", "longName": "9954481 - Disclosure - Supplemental Balance Sheet Information - Narrative (Details)", "shortName": "Supplemental Balance Sheet Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails", "longName": "9954482 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.exicuretx.com/role/LeasesNarrativeDetails", "longName": "9954483 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.exicuretx.com/role/LeasesLeaseCostsDetails", "longName": "9954484 - Disclosure - Leases - Lease Costs (Details)", "shortName": "Leases - Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.exicuretx.com/role/LeasesSubleaseReceiptsDetails", "longName": "9954485 - Disclosure - Leases - Sublease Receipts (Details)", "shortName": "Leases - Sublease Receipts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubleaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubleaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails", "longName": "9954486 - Disclosure - Investment in Convertible Notes Receivable - Narrative (Details)", "shortName": "Investment in Convertible Notes Receivable - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "xcur:NumberOfSubscriptionAgreementsEntered", "unitRef": "agreement", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R40": { "role": "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "longName": "9954487 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Details)", "shortName": "Stockholders' Equity - Preferred and Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "xcur:CommonStockVotingRightsForEachShare", "unitRef": "vote", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R41": { "role": "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "longName": "9954488 - Disclosure - Stockholders' Equity - Securities Purchase Agreement (Details)", "shortName": "Stockholders' Equity - Securities Purchase Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-47", "name": "xcur:RegistrationRightsAgreementRequiredFilingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "xcur:RegistrationRightsAgreementRequiredFilingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails", "longName": "9954489 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)", "shortName": "Stockholders' Equity - Common Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "longName": "9954490 - Disclosure - Equity-Based Compensation - Narrative (Details)", "shortName": "Equity-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails", "longName": "9954491 - Disclosure - Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details)", "shortName": "Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "longName": "9954492 - Disclosure - Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details)", "shortName": "Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails", "longName": "9954493 - Disclosure - Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)", "shortName": "Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-25", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-25", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails", "longName": "9954494 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)", "shortName": "Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R48": { "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "longName": "9954495 - Disclosure - Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details)", "shortName": "Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-86", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-86", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails", "longName": "9954496 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R50": { "role": "http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails", "longName": "9954497 - Disclosure - Loss Per Common Share - Schedule of Computation of loss per common share (Details)", "shortName": "Loss Per Common Share - Schedule of Computation of loss per common share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "longName": "9954498 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities (Details)", "shortName": "Loss Per Common Share - Schedule of Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "longName": "9954499 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-105", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "unique": true } }, "R53": { "role": "http://www.exicuretx.com/role/CommitmentandContingenciesNarrativeDetails", "longName": "9954500 - Disclosure - Commitment and Contingencies - Narrative (Details)", "shortName": "Commitment and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails", "longName": "9954501 - Disclosure - Related-Party Transactions - Narrative (Details)", "shortName": "Related-Party Transactions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-121", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-121", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.exicuretx.com/role/LicenseAgreementDetails", "longName": "9954502 - Disclosure - License Agreement (Details)", "shortName": "License Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-122", "name": "xcur:ProceedsFromPatentLicenseAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "xcur:ProceedsFromPatentLicenseAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.exicuretx.com/role/SubsequentEventsDetails", "longName": "9954503 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-123", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-123", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "xcur-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r10", "r599" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r26", "r97", "r444" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r649" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r46", "r599", "r771" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in- Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r315", "r316", "r317", "r467", "r706", "r707", "r708", "r753", "r772" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r655" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r655" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r655" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r655" ] }, "xcur_AdjustmentsToAdditionalPaidInCapitalDecreaseRelatedToReclassification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "AdjustmentsToAdditionalPaidInCapitalDecreaseRelatedToReclassification", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of common stock warrants to liability", "label": "Adjustments To Additional Paid in Capital, Decrease Related To Reclassification", "documentation": "Adjustments To Additional Paid in Capital, Decrease Related To Reclassification" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r31", "r32", "r281" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "xcur_AggregatePaymentsMadeToDateForLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "AggregatePaymentsMadeToDateForLicenseAgreements", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate consideration paid to NU for agreement obligations", "label": "Aggregate Payments Made To Date For License Agreements", "documentation": "Aggregate Payments Made To Date For License Agreements" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r620", "r631", "r641", "r666" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r623", "r634", "r644", "r669" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r655" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r662" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r627", "r635", "r645", "r662", "r670", "r674", "r682" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r680" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r310", "r318" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r147" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r19" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r74", "r99", "r118", "r154", "r161", "r165", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r333", "r335", "r357", "r437", "r504", "r599", "r611", "r722", "r723", "r760" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r93", "r104", "r118", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r333", "r335", "r357", "r599", "r722", "r723", "r760" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r34" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale securities", "verboseLabel": "Investment in convertible notes receivable", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r175", "r211", "r433", "r712" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r677" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r678" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r673" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r673" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r673" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r673" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r673" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r673" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r676" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r675" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r674" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r674" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "xcur_BiopharmaceuticalCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "BiopharmaceuticalCompanyMember", "presentation": [ "http://www.exicuretx.com/role/LicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biopharmaceutical Company", "label": "Biopharmaceutical Company [Member]", "documentation": "Biopharmaceutical Company" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business, Basis of Presentation and Going Concern", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r41", "r63", "r64" ] }, "xcur_CBIUSADGPCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "CBIUSADGPCoLtdMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CBI USA & DGP Co. Ltd", "label": "CBI USA & DGP Co. Ltd [Member]", "documentation": "CBI USA & DGP Co. Ltd" } } }, "auth_ref": [] }, "xcur_CBIUSAIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "CBIUSAIncMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CBI USA, Inc", "label": "CBI USA, Inc [Member]", "documentation": "CBI USA, Inc" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r18", "r95", "r572" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents:", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r18", "r60", "r115" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r60" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r653" ] }, "xcur_ChicagoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ChicagoMember", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chicago", "label": "Chicago [Member]", "documentation": "Chicago" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r89", "r100", "r101", "r102", "r118", "r141", "r142", "r144", "r146", "r152", "r153", "r203", "r224", "r226", "r227", "r228", "r231", "r232", "r251", "r252", "r255", "r258", "r265", "r357", "r458", "r459", "r460", "r461", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r492", "r513", "r535", "r552", "r553", "r554", "r555", "r556", "r688", "r703", "r709" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails", "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r266" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares exercisable for each warrant (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares called by warrants (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r266" ] }, "xcur_ClassOfWarrantOrRightNumberOfSecuritiesSettledInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesSettledInPeriod", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants settled (in shares)", "label": "Class Of Warrant Or Right, Number Of Securities Settled In Period", "documentation": "Class Of Warrant Or Right, Number Of Securities Settled In Period" } } }, "auth_ref": [] }, "xcur_ClassOfWarrantOrRightOwnershipPercentageLimitation": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ClassOfWarrantOrRightOwnershipPercentageLimitation", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage limitation (as a percent)", "label": "Class Of Warrant Or Right, Ownership Percentage Limitation", "documentation": "Class Of Warrant Or Right, Ownership Percentage Limitation" } } }, "auth_ref": [] }, "xcur_ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ClassOfWarrantOrRightOwnershipPercentageLimitationAtElectionOfPurchaser", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage limitation at election of purchaser (as a percent)", "label": "Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser", "documentation": "Class Of Warrant Or Right, Ownership Percentage Limitation At Election Of Purchaser" } } }, "auth_ref": [] }, "xcur_ClassOfWarrantOrRightPaymentForLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ClassOfWarrantOrRightPaymentForLiability", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for warrant liability", "label": "Class Of Warrant Or Right, Payment For Liability", "documentation": "Class Of Warrant Or Right, Payment For Liability" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r654" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r654" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 11)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r16", "r39", "r438", "r491" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.exicuretx.com/role/CommitmentandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r67", "r218", "r219", "r559", "r721" ] }, "xcur_CommonStockAndAccompanyingWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "CommonStockAndAccompanyingWarrantMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock And Accompanying Warrant", "label": "Common Stock And Accompanying Warrant [Member]", "documentation": "Common Stock And Accompanying Warrant" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r601", "r602", "r603", "r605", "r606", "r607", "r608", "r706", "r707", "r753", "r770", "r772" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r45", "r492" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r45", "r492", "r510", "r772", "r773" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 8,650,950 issued and outstanding, March\u00a031, 2024; 8,650,753 issued and outstanding, December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r45", "r441", "r599" ] }, "xcur_CommonStockVotingRightsForEachShare": { "xbrltype": "integerItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "CommonStockVotingRightsForEachShare", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, voting rights for each share", "label": "Common Stock, Voting Rights For Each Share", "documentation": "Common Stock, Voting Rights For Each Share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r659" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r658" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r660" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r657" ] }, "xcur_ComputersandSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ComputersandSoftwareMember", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computers and software", "label": "Computers and Software [Member]", "documentation": "Computers and Software [Member]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r33", "r577" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.exicuretx.com/role/LicenseAgreementDetails", "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r122", "r123", "r236", "r253", "r383", "r574", "r576" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "xcur_DGPCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "DGPCoLtdMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DGP Co. Ltd", "label": "DGP Co. Ltd [Member]", "documentation": "DGP Co. Ltd" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r9", "r42", "r43", "r75", "r76", "r124", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r365", "r584", "r585", "r586", "r587", "r588", "r704" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r35", "r36", "r233", "r365", "r585", "r586" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r14", "r234" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r15", "r124", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r365", "r584", "r585", "r586", "r587", "r588", "r704" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "xcur_DebtSecuritiesAvailableForSaleFaceValueConversionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "DebtSecuritiesAvailableForSaleFaceValueConversionPercentage", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face value conversion percentage", "label": "Debt Securities, Available-for-Sale, Face Value Conversion Percentage", "documentation": "Debt Securities, Available-for-Sale, Face Value Conversion Percentage" } } }, "auth_ref": [] }, "xcur_DebtSecuritiesAvailableForSalePeriodInBetweenReoccurringPutOption": { "xbrltype": "durationItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "DebtSecuritiesAvailableForSalePeriodInBetweenReoccurringPutOption", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period in between reoccurring put option", "label": "Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option", "documentation": "Debt Securities, Available-for-Sale, Period In Between Reoccurring Put Option" } } }, "auth_ref": [] }, "xcur_DebtSecuritiesAvailableForSaleStatedYield": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "DebtSecuritiesAvailableForSaleStatedYield", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated yield", "label": "Debt Securities, Available-for-Sale, Stated Yield", "documentation": "Debt Securities, Available-for-Sale, Stated Yield" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationNarrativeDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r4" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r279", "r283", "r311", "r312", "r314", "r595" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r615" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r648" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per common share (in dollars per share)", "verboseLabel": "Loss per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r110", "r130", "r131", "r132", "r133", "r134", "r139", "r141", "r144", "r145", "r146", "r150", "r346", "r347", "r434", "r449", "r578" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per common share (in dollars per share)", "verboseLabel": "Loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r110", "r130", "r131", "r132", "r133", "r134", "r141", "r144", "r145", "r146", "r150", "r346", "r347", "r434", "r449", "r578" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Common Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r19", "r20" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r138", "r147", "r148", "r149" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate (as a percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r322" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll-related expenses", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r313" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense recognition period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r313" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option", "verboseLabel": "Options to purchase common stock", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r613" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r613" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r613" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r687" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r613" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r613" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r613" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r613" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scientific equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r91", "r107", "r108", "r109", "r125", "r126", "r127", "r129", "r135", "r137", "r151", "r204", "r205", "r267", "r315", "r316", "r317", "r326", "r327", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r358", "r359", "r360", "r361", "r362", "r363", "r376", "r452", "r453", "r454", "r467", "r535" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r656" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r620", "r631", "r641", "r666" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r617", "r628", "r638", "r663" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r662" ] }, "xcur_ExicureInc.2017EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ExicureInc.2017EquityIncentivePlanMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exicure, Inc. 2017 Equity Incentive Plan", "label": "Exicure, Inc. 2017 Equity Incentive Plan [Member]", "documentation": "Exicure, Inc. 2017 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "xcur_ExicureOpCo2015EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ExicureOpCo2015EquityIncentivePlanMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exicure OpCo 2015 Equity Incentive Plan", "label": "Exicure OpCo 2015 Equity Incentive Plan [Member]", "documentation": "Exicure OpCo 2015 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r349", "r350", "r353" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r349", "r350", "r353" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r241", "r271", "r272", "r273", "r274", "r275", "r276", "r350", "r391", "r392", "r393", "r585", "r586", "r591", "r592", "r593" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r349", "r350", "r351", "r352", "r354" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r348" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r241", "r271", "r276", "r350", "r391", "r591", "r592", "r593" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r241", "r271", "r276", "r350", "r392", "r585", "r586", "r591", "r592", "r593" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r241", "r271", "r272", "r273", "r274", "r275", "r276", "r350", "r393", "r585", "r586", "r591", "r592", "r593" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r241", "r271", "r272", "r273", "r274", "r275", "r276", "r391", "r392", "r393", "r585", "r586", "r591", "r592", "r593" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r348", "r354" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r214", "r249", "r263", "r343", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r448", "r582", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r714", "r715", "r716", "r717" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.exicuretx.com/role/LicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r420" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r624", "r635", "r645", "r670" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r624", "r635", "r645", "r670" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r624", "r635", "r645", "r670" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r624", "r635", "r645", "r670" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r624", "r635", "r645", "r670" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r4" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r54", "r515" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r53" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r51", "r78", "r154", "r160", "r164", "r166", "r435", "r446", "r580" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r216", "r217", "r520" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r217", "r520" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.exicuretx.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r119", "r320", "r323", "r324", "r325", "r328", "r330", "r331", "r332", "r463" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/IncomeTaxesNarrativeDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r82", "r88", "r136", "r137", "r158", "r321", "r329", "r450" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncurrent assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r700" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r627", "r635", "r645", "r662", "r670", "r674", "r682" ] }, "xcur_InitialEmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "InitialEmployeeStockOptionMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Employee Stock Option", "label": "Initial Employee Stock Option [Member]", "documentation": "Initial Employee Stock Option [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r680" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r616", "r686" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r616", "r686" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r616", "r686" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.exicuretx.com/role/LicenseAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r215" ] }, "us-gaap_InvestmentIncomeDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeDividend", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend income", "label": "Investment Income, Dividend", "documentation": "Amount of dividend income on nonoperating securities." } } }, "auth_ref": [ "r55" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r56", "r157" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Convertible Notes Receivable", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r72", "r80", "r81", "r90", "r171", "r172", "r355", "r356" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r371", "r598" ] }, "xcur_LeaseCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LeaseCostCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease costs", "label": "Lease, Cost, Current", "documentation": "Lease, Cost, Current" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Costs", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r757" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r370" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r370" ] }, "xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, annual rent payment", "label": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months", "documentation": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months" } } }, "auth_ref": [] }, "xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LesseeOperatingLeaseBaseRentAnnualPercentageIncrease", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, base rent annual percentage increase (as a percent)", "label": "Lessee, Operating Lease, Base Rent Annual Percentage Increase", "documentation": "Lessee, Operating Lease, Base Rent Annual Percentage Increase" } } }, "auth_ref": [] }, "xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, estimated rental payment over lease term", "label": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term", "documentation": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term" } } }, "auth_ref": [] }, "xcur_LesseeOperatingLeaseLeaseArea": { "xbrltype": "areaItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LesseeOperatingLeaseLeaseArea", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease area", "label": "Lessee, Operating Lease, Lease Area", "documentation": "Lessee, Operating Lease, Lease Area" } } }, "auth_ref": [] }, "xcur_LesseeOperatingLeaseNumberOfExtensions": { "xbrltype": "integerItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LesseeOperatingLeaseNumberOfExtensions", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, number of extensions", "label": "Lessee, Operating Lease, Number of Extensions", "documentation": "Lessee, Operating Lease, Number of Extensions" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r756" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, contract term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r756" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.exicuretx.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r366" ] }, "xcur_LesseeOperatingSubleasePercentageOfOfficeSpaceSubleased": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LesseeOperatingSubleasePercentageOfOfficeSpaceSubleased", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease percentage of office space subtenant (as a percent)", "label": "Lessee, Operating Sublease, Percentage Of Office Space Subleased", "documentation": "Lessee, Operating Sublease, Percentage Of Office Space Subleased" } } }, "auth_ref": [] }, "xcur_LesseeOperatingSubleasePeriodOfNoRentCost": { "xbrltype": "durationItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "LesseeOperatingSubleasePeriodOfNoRentCost", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of no rental cost", "label": "Lessee, Operating Sublease, Period Of No Rent Cost", "documentation": "Lessee, Operating Sublease, Period Of No Rent Cost" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r11", "r118", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r334", "r335", "r336", "r357", "r490", "r579", "r611", "r722", "r760", "r761" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r50", "r77", "r443", "r599", "r705", "r718", "r755" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r13", "r94", "r118", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r334", "r335", "r336", "r357", "r599", "r722", "r760", "r761" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r278", "r418", "r451", "r482", "r483", "r543", "r545", "r547", "r548", "r550", "r569", "r570", "r581", "r589", "r594", "r600", "r724", "r762", "r763", "r764", "r765", "r766", "r767" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r654" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r654" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r278", "r418", "r451", "r482", "r483", "r543", "r545", "r547", "r548", "r550", "r569", "r570", "r581", "r589", "r594", "r600", "r724", "r762", "r763", "r764", "r765", "r766", "r767" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r673" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r726" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r681" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r655" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r114" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r114" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r60", "r61", "r62" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r52", "r62", "r79", "r92", "r105", "r106", "r109", "r118", "r128", "r130", "r131", "r132", "r133", "r136", "r137", "r143", "r154", "r160", "r164", "r166", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r347", "r357", "r447", "r512", "r533", "r534", "r580", "r609", "r722" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r654" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r624", "r635", "r645", "r662", "r670" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r652" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r651" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r662" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r681" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r681" ] }, "xcur_NonemployeeDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "NonemployeeDirectorMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-employee Director", "label": "Non-employee Director [Member]", "documentation": "Non-employee Director [Member]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r57" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableMember", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable", "label": "Notes Receivable [Member]", "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "xcur_NotesReceivableOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "NotesReceivableOneMember", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable, One", "label": "Notes Receivable, One [Member]", "documentation": "Notes Receivable, One" } } }, "auth_ref": [] }, "xcur_NotesReceivableTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "NotesReceivableTwoMember", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable, Two", "label": "Notes Receivable, Two [Member]", "documentation": "Notes Receivable, Two" } } }, "auth_ref": [] }, "xcur_NumberOfSubscriptionAgreementsEntered": { "xbrltype": "integerItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "NumberOfSubscriptionAgreementsEntered", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of subscription agreements entered into", "label": "Number Of Subscription Agreements Entered", "documentation": "Number Of Subscription Agreements Entered" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r154", "r160", "r164", "r166", "r580" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r372", "r598" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r368" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease liability, noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r368" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, cash payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r369", "r375" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r367" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use asset", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r701" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofAccruedexpensesandothercurrentliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r12" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "totalLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r98" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r58" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r654" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r698", "r719" ] }, "us-gaap_OtherReceivablesGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesGrossCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivable", "label": "Other Receivables, Gross, Current", "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r103" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r622", "r633", "r643", "r668" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r625", "r636", "r646", "r671" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r625", "r636", "r646", "r671" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r650" ] }, "xcur_PaymentsOfCommonStockFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PaymentsOfCommonStockFinancingCosts", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of common stock financing costs", "label": "Payments Of Common Stock Financing Costs", "documentation": "Payments Of Common Stock Financing Costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for minimum statutory tax withholding related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r113" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r653" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r653" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r652" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r662" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r655" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r651" ] }, "xcur_PerformanceBasedRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PerformanceBasedRestrictedStockMember", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Performance stock units", "label": "Performance Based Restricted Stock [Member]", "documentation": "Performance Based Restricted Stock" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ] }, "xcur_PreFundedWarrantsAndAccompanyingWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PreFundedWarrantsAndAccompanyingWarrantMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants And Accompanying Warrant", "label": "Pre-Funded Warrants And Accompanying Warrant [Member]", "documentation": "Pre-Funded Warrants And Accompanying Warrant" } } }, "auth_ref": [] }, "xcur_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants", "label": "Pre-Funded Warrants [Member]", "documentation": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r44", "r251" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r44", "r492" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r44", "r251" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquityPreferredandCommonStockDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r44", "r492", "r510", "r772", "r773" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, March\u00a031, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r44", "r440", "r599" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r699" ] }, "xcur_PrepaidFranchiseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PrepaidFranchiseTax", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid franchise tax", "label": "Prepaid Franchise Tax", "documentation": "Prepaid Franchise Tax" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r573", "r583", "r719" ] }, "xcur_PrepaidInsuranceNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PrepaidInsuranceNoncurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance, Noncurrent", "documentation": "Prepaid Insurance, Noncurrent" } } }, "auth_ref": [] }, "xcur_PrepaidProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PrepaidProfessionalFeesCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid professional fees", "label": "Prepaid Professional Fees, Current", "documentation": "Prepaid Professional Fees, Current" } } }, "auth_ref": [] }, "xcur_PrepaidSoftwareCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PrepaidSoftwareCurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid software", "label": "Prepaid Software, Current", "documentation": "Prepaid Software, Current" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from common stock offering", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "xcur_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds From Issuance Of Common Stock And Warrants", "documentation": "Proceeds From Issuance Of Common Stock And Warrants" } } }, "auth_ref": [] }, "xcur_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfPlacementAgentFeeAndOtherOfferingExpensesPayable", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable", "documentation": "Proceeds from Issuance of Common Stock And Warrants Net of Placement Agent Fee and Other Offering Expenses Payable" } } }, "auth_ref": [] }, "xcur_ProceedsFromPatentLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ProceedsFromPatentLicenseAgreement", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/LicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from patent license agreement", "label": "Proceeds From Patent License Agreement", "documentation": "Proceeds From Patent License Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale or maturity of available-for-sale securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r111", "r112", "r713" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r59" ] }, "xcur_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "PromissoryNoteMember", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory Note", "label": "Promissory Note [Member]", "documentation": "Promissory Note" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r66", "r96", "r445" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r436", "r445", "r599" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r66" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r650" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r650" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r270", "r278", "r306", "r307", "r308", "r394", "r418", "r451", "r482", "r483", "r543", "r545", "r547", "r548", "r550", "r569", "r570", "r581", "r589", "r594", "r600", "r603", "r720", "r724", "r763", "r764", "r765", "r766", "r767" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r270", "r278", "r306", "r307", "r308", "r394", "r418", "r451", "r482", "r483", "r543", "r545", "r547", "r548", "r550", "r569", "r570", "r581", "r589", "r594", "r600", "r603", "r720", "r724", "r763", "r764", "r765", "r766", "r767" ] }, "xcur_ReclassificationOfCommonStockWarrantsToLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ReclassificationOfCommonStockWarrantsToLiability", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of common stock warrants to liability", "label": "Reclassification Of Common Stock Warrants To Liability", "documentation": "Reclassification Of Common Stock Warrants To Liability" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r617", "r628", "r638", "r663" ] }, "xcur_RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "RegistrationRightsAgreementLiquidationDamagesPayableAsAPercentOfAmountInvestedIfFiledLate", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registration rights agreement, liquidation damages payable as a percent of amount invested, if filed late (as a percent)", "label": "Registration Rights Agreement, Liquidation Damages Payable As A Percent Of Amount Invested, If Filed Late", "documentation": "Registration Rights Agreement, Liquidation Damages Payable If Filed Late, As A Percent Of Amount Invested" } } }, "auth_ref": [] }, "xcur_RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "RegistrationRightsAgreementLiquidationDamagesPayableIfFiledLateMeasurementTerm", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registration rights agreement, liquidation damages payable if filed late, measurement term", "label": "Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term", "documentation": "Registration Rights Agreement, Liquidation Damages Payable If Filed Late, Measurement Term" } } }, "auth_ref": [] }, "xcur_RegistrationRightsAgreementProRataAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "RegistrationRightsAgreementProRataAccrual", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro rata accrual", "label": "Registration Rights Agreement, Pro Rata Accrual", "documentation": "Registration Rights Agreement, Pro Rata Accrual" } } }, "auth_ref": [] }, "xcur_RegistrationRightsAgreementProRataPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "RegistrationRightsAgreementProRataPayment", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro rata payment", "label": "Registration Rights Agreement, Pro Rata Payment", "documentation": "Registration Rights Agreement, Pro Rata Payment" } } }, "auth_ref": [] }, "xcur_RegistrationRightsAgreementRequiredFilingTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "RegistrationRightsAgreementRequiredFilingTerm", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registration rights agreement, required filing term", "label": "Registration Rights Agreement, Required Filing Term", "documentation": "Registration Rights Agreement, Required Filing Term" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r277", "r380", "r381", "r485", "r486", "r487", "r488", "r489", "r509", "r511", "r542" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r120", "r121", "r380", "r381", "r382", "r383", "r485", "r486", "r487", "r488", "r489", "r509", "r511", "r542" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of transaction", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r38", "r380" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r516", "r517", "r520" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r277", "r380", "r381", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r485", "r486", "r487", "r488", "r489", "r509", "r511", "r542", "r759" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.exicuretx.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related-Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r377", "r378", "r379", "r381", "r384", "r464", "r465", "r466", "r518", "r519", "r520", "r539", "r541" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.exicuretx.com/role/LicenseAgreementDetails", "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails", "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r122", "r123", "r236", "r253", "r383", "r575", "r576" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r40", "r319", "r768" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r618", "r629", "r639", "r664" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r619", "r630", "r640", "r665" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r626", "r637", "r647", "r672" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other noncurrent assets", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r18", "r73", "r95", "r115", "r439" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r95" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r83", "r697", "r702" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r47", "r69", "r442", "r455", "r456", "r462", "r493", "r599" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r91", "r125", "r126", "r127", "r129", "r135", "r137", "r204", "r205", "r315", "r316", "r317", "r326", "r327", "r337", "r339", "r340", "r342", "r345", "r452", "r454", "r467", "r772" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r155", "r156", "r159", "r162", "r163", "r167", "r168", "r170", "r268", "r269", "r419" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r681" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r681" ] }, "xcur_SaleOfStockAndWarrantsPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SaleOfStockAndWarrantsPricePerShare", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price (in dollars per share)", "label": "Sale Of Stock And Warrants, Price Per Share", "documentation": "Sale Of Stock And Warrants, Price Per Share" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration for stock transaction", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "xcur_SaleOfStockConsiderationReceivedOnTransactionGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration received, gross", "label": "Sale Of Stock, Consideration Received On Transaction, Gross", "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "xcur_SaleOfStockNumberOfSharesIssuedInTransactionPercentageSubsequentlySold": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SaleOfStockNumberOfSharesIssuedInTransactionPercentageSubsequentlySold", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares subsequently sold at closing", "label": "Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold", "documentation": "Sale Of Stock, Number Of Shares Issued In Transaction, Percentage Subsequently Sold" } } }, "auth_ref": [] }, "xcur_SaleOfStockNumberOfWarrantsIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SaleOfStockNumberOfWarrantsIssuedInTransaction", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued in sale of stock (in shares)", "label": "Sale Of Stock, Number Of Warrants Issued In Transaction", "documentation": "Sale Of Stock, Number Of Warrants Issued In Transaction" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership after transaction (as a percent)", "label": "Sale of Stock, Percentage of Ownership after Transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales price of shares issued in transaction (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued expenses and other current liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184" ] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity-Based Compensation Expense Classification in Statement of Operations", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Loss per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r710" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r349", "r350" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.exicuretx.com/role/LicenseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r24", "r25", "r420" ] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Noncurrent Assets", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": [ "r697" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationScheduleofPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r37", "r38", "r516", "r517", "r520" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r280", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r7", "r8", "r29" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Unit Awards Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r612" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r614" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r168", "r169", "r479", "r480", "r481", "r544", "r546", "r549", "r551", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r590", "r603", "r725", "r769" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r595" ] }, "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly vesting percentage (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Monthly Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r300" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r300" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested balance - beginning of period (in shares)", "periodEndLabel": "Unvested balance - end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r295", "r296" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested balance - beginning of period (in dollars per share)", "periodEndLabel": "Unvested balance - end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r295", "r296" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r299" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r299" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of common stock option (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r307" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r308" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r306" ] }, "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in number of shares available for grant (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofEquityBasedCompensationExpenseClassificationinStatementofOperationsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r280", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309" ] }, "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum contribution amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum ESPP contribution rate as a percentage of compensation (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares per employee in purchase period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted Stock Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares allowable annually under the plan (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r597" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r28" ] }, "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued for each vested restricted stock unit (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r289" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r289" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r293" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r291" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r301" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares outstanding, beginning period (in shares)", "periodEndLabel": "Shares outstanding, ending period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r287", "r288" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding beginning balance (in dollars per share)", "periodEndLabel": "Outstanding ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r287", "r288" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value (thousands)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r303" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r303" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, weighted-average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r303" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding shares allowable as annual increase (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofRestrictedStockUnitAwardsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r292" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r293" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r291" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of underlying common stock (in dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r727" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r596" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r305" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r28" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, weighted-average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r28" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r70" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r304" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP purchase price as a percentage of market price (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeiture rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate" } } }, "auth_ref": [] }, "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized, percentage of common stock outstanding (as a percent)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding" } } }, "auth_ref": [] }, "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized, potential maximum additional shares (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term lease costs", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r373", "r598" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.exicuretx.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r63", "r116" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r89", "r100", "r101", "r102", "r118", "r141", "r142", "r144", "r146", "r152", "r153", "r203", "r224", "r226", "r227", "r228", "r231", "r232", "r251", "r252", "r255", "r258", "r265", "r357", "r458", "r459", "r460", "r461", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r492", "r513", "r535", "r552", "r553", "r554", "r555", "r556", "r688", "r703", "r709" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r17", "r91", "r107", "r108", "r109", "r125", "r126", "r127", "r129", "r135", "r137", "r151", "r204", "r205", "r267", "r315", "r316", "r317", "r326", "r327", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r358", "r359", "r360", "r361", "r362", "r363", "r376", "r452", "r453", "r454", "r467", "r535" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.exicuretx.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r168", "r169", "r479", "r480", "r481", "r544", "r546", "r549", "r551", "r558", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r571", "r590", "r603", "r725", "r769" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r126", "r127", "r151", "r419", "r457", "r478", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r505", "r506", "r507", "r508", "r509", "r511", "r514", "r515", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r604" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r125", "r126", "r127", "r151", "r419", "r457", "r478", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r505", "r506", "r507", "r508", "r509", "r511", "r514", "r515", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r604" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r621", "r632", "r642", "r667" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r44", "r45", "r69", "r458", "r535", "r553" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units and related repurchases (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r6", "r44", "r45", "r69" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercise (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r6", "r44", "r45", "r69", "r292" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r6", "r44", "r45", "r69", "r467", "r535", "r553", "r610" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units and related repurchases", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r6", "r69" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r45", "r48", "r49", "r65", "r494", "r510", "r536", "r537", "r599", "r611", "r705", "r718", "r755", "r772" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r68", "r117", "r250", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r267", "r344", "r538", "r540", "r557" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.exicuretx.com/role/LeasesSubleaseReceiptsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease amounts paid to landlord", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r374", "r598" ] }, "xcur_SubsequentEmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SubsequentEmployeeStockOptionMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Employee Stock Option", "label": "Subsequent Employee Stock Option [Member]", "documentation": "Subsequent Employee Stock Option [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r364", "r386" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r364", "r386" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r364", "r386" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r364", "r386" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.exicuretx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r364", "r386" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.exicuretx.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r385", "r387" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, Sale of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r696" ] }, "xcur_SupplementalBalanceSheetInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "SupplementalBalanceSheetInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information [Abstract]", "label": "Supplemental Balance Sheet Information [Abstract]", "documentation": "Supplemental Balance Sheet Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r661" ] }, "xcur_ThirdPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ThirdPartyMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party", "label": "Third Party [Member]", "documentation": "Third Party" } } }, "auth_ref": [] }, "xcur_ThirdPartySaleOfCompanyStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "ThirdPartySaleOfCompanyStockMember", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Sale of Company Stock", "label": "Third Party Sale Of Company Stock [Member]", "documentation": "Third Party Sale Of Company Stock" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r711", "r758" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r653" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r660" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r680" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r682" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.exicuretx.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.exicuretx.com/role/InvestmentinConvertibleNotesReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r249", "r263", "r343", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r448", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r714", "r715", "r716", "r717" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r683" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r684" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r682" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r682" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r685" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r683" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r679" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r21", "r22", "r23", "r84", "r85", "r86", "r87" ] }, "xcur_VariableLeaseCostNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.exicuretx.com/20240331", "localname": "VariableLeaseCostNet", "crdr": "debit", "calculation": { "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.exicuretx.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost, Net", "documentation": "Variable Lease, Cost, Net" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofAntidilutiveSecuritiesDetails", "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "verboseLabel": "Warrants to purchase common stock", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r601", "r602", "r605", "r606", "r607", "r608" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.exicuretx.com/role/StockholdersEquitySecuritiesPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability, measurement input, term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r754" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofAssumptionsUsedtoDetermineFairValueofCommonStockOptionGrantsDetails", "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r569", "r570", "r762", "r764", "r767" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average diluted common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r140", "r146" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.exicuretx.com/role/LossPerCommonShareScheduleofComputationoflosspercommonshareDetails", "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average basic common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r139", "r146" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r688": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 75 0001698530-24-000068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001698530-24-000068-xbrl.zip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�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end XML 77 xcur-20240331_htm.xml IDEA: XBRL DOCUMENT 0001698530 2024-01-01 2024-03-31 0001698530 2024-06-10 0001698530 2024-03-31 0001698530 2023-12-31 0001698530 2023-01-01 2023-03-31 0001698530 us-gaap:CommonStockMember 2023-12-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001698530 us-gaap:RetainedEarningsMember 2023-12-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001698530 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001698530 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001698530 us-gaap:CommonStockMember 2024-03-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001698530 us-gaap:RetainedEarningsMember 2024-03-31 0001698530 us-gaap:CommonStockMember 2022-12-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001698530 us-gaap:RetainedEarningsMember 2022-12-31 0001698530 2022-12-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001698530 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001698530 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001698530 us-gaap:CommonStockMember 2023-03-31 0001698530 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001698530 us-gaap:RetainedEarningsMember 2023-03-31 0001698530 2023-03-31 0001698530 us-gaap:EquipmentMember 2024-03-31 0001698530 us-gaap:EquipmentMember 2023-12-31 0001698530 xcur:ComputersandSoftwareMember 2024-03-31 0001698530 xcur:ComputersandSoftwareMember 2023-12-31 0001698530 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001698530 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001698530 xcur:ChicagoMember 2020-07-01 2020-07-01 0001698530 xcur:ChicagoMember 2020-07-01 0001698530 xcur:ChicagoMember 2023-05-04 2023-05-04 0001698530 us-gaap:NotesReceivableMember 2023-05-01 2023-05-31 0001698530 xcur:NotesReceivableTwoMember 2023-05-31 0001698530 xcur:NotesReceivableOneMember 2023-05-31 0001698530 us-gaap:NotesReceivableMember 2023-05-31 0001698530 us-gaap:NotesReceivableMember 2024-03-01 2024-03-31 0001698530 us-gaap:PrivatePlacementMember 2022-09-26 2022-09-26 0001698530 us-gaap:PrivatePlacementMember 2022-09-26 0001698530 us-gaap:PrivatePlacementMember 2023-02-24 2023-02-24 0001698530 xcur:DGPCoLtdMember xcur:ThirdPartySaleOfCompanyStockMember xcur:CBIUSAIncMember 2023-06-23 2023-06-23 0001698530 xcur:ThirdPartyMember xcur:ThirdPartySaleOfCompanyStockMember xcur:DGPCoLtdMember 2024-02-29 0001698530 xcur:ThirdPartyMember xcur:ThirdPartySaleOfCompanyStockMember xcur:DGPCoLtdMember 2024-02-01 2024-02-29 0001698530 us-gaap:PrivatePlacementMember xcur:CBIUSADGPCoLtdMember 2024-01-01 2024-03-31 0001698530 2022-09-26 2022-09-26 0001698530 xcur:CBIUSAIncMember 2024-01-01 2024-03-31 0001698530 xcur:DGPCoLtdMember 2024-03-31 0001698530 us-gaap:CommonStockMember 2021-12-16 2021-12-16 0001698530 us-gaap:CommonStockMember 2021-12-16 0001698530 xcur:PreFundedWarrantsMember 2021-12-16 2021-12-16 0001698530 us-gaap:WarrantMember 2021-12-16 2021-12-16 0001698530 xcur:CommonStockAndAccompanyingWarrantMember 2021-12-16 2021-12-16 0001698530 xcur:PreFundedWarrantsAndAccompanyingWarrantMember 2021-12-16 2021-12-16 0001698530 xcur:PreFundedWarrantsMember 2021-12-16 0001698530 us-gaap:WarrantMember 2021-12-16 0001698530 2021-12-16 0001698530 2021-12-16 2021-12-16 0001698530 2021-12-31 0001698530 2023-06-23 2023-06-23 0001698530 xcur:ExicureInc.2017EquityIncentivePlanMember 2017-09-22 0001698530 xcur:ExicureOpCo2015EquityIncentivePlanMember 2017-09-22 0001698530 xcur:ExicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-03-31 0001698530 xcur:ExicureInc.2017EquityIncentivePlanMember 2024-03-31 0001698530 us-gaap:EmployeeStockOptionMember xcur:ExicureInc.2017EquityIncentivePlanMember 2023-01-01 0001698530 xcur:InitialEmployeeStockOptionMember xcur:ExicureInc.2017EquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-03-31 0001698530 xcur:InitialEmployeeStockOptionMember xcur:ExicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-03-31 0001698530 xcur:SubsequentEmployeeStockOptionMember xcur:ExicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-03-31 0001698530 xcur:NonemployeeDirectorMember xcur:InitialEmployeeStockOptionMember xcur:ExicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-03-31 0001698530 xcur:NonemployeeDirectorMember xcur:SubsequentEmployeeStockOptionMember xcur:ExicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-03-31 0001698530 us-gaap:EmployeeStockOptionMember xcur:ExicureInc.2017EquityIncentivePlanMember 2024-01-01 2024-03-31 0001698530 us-gaap:EmployeeStockMember 2017-09-30 0001698530 us-gaap:EmployeeStockMember 2017-09-01 2017-09-30 0001698530 us-gaap:EmployeeStockMember 2023-01-01 2023-01-01 0001698530 us-gaap:EmployeeStockMember 2024-03-31 0001698530 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001698530 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001698530 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001698530 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001698530 srt:MinimumMember 2023-01-01 2023-03-31 0001698530 srt:MaximumMember 2023-01-01 2023-03-31 0001698530 srt:WeightedAverageMember 2023-01-01 2023-03-31 0001698530 srt:WeightedAverageMember 2023-03-31 0001698530 2023-01-01 2023-12-31 0001698530 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001698530 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001698530 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001698530 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001698530 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001698530 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001698530 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001698530 xcur:PerformanceBasedRestrictedStockMember 2024-01-01 2024-03-31 0001698530 xcur:PerformanceBasedRestrictedStockMember 2023-01-01 2023-03-31 0001698530 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001698530 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2024-03-31 0001698530 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2024-03-31 0001698530 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2024-03-31 0001698530 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2024-03-31 0001698530 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2023-12-31 0001698530 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2023-12-31 0001698530 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2023-12-31 0001698530 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NotesReceivableMember 2023-12-31 0001698530 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001698530 us-gaap:RelatedPartyMember 2023-02-27 2023-02-27 0001698530 xcur:BiopharmaceuticalCompanyMember 2024-02-05 2024-02-05 0001698530 xcur:PromissoryNoteMember us-gaap:SubsequentEventMember 2024-05-03 0001698530 xcur:DGPCoLtdMember xcur:PromissoryNoteMember us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2024-06-03 0001698530 xcur:DGPCoLtdMember xcur:PromissoryNoteMember us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2024-06-03 2024-06-03 shares iso4217:USD iso4217:USD shares utr:sqft xcur:extension_period pure xcur:agreement xcur:vote 0001698530 --12-31 2024 Q1 false 0.0208 0.0208 0.0278 0.0833 10-Q true 2024-03-31 false 001-39011 EXICURE, INC. DE 81-5333008 2430 N. Halsted St. Chicago IL 60614 (847) 673-1700 Common Stock, par value $0.0001 per share XCUR NASDAQ Yes Yes Non-accelerated Filer true false false 8651148 366000 816000 1000 15000 1096000 1193000 1463000 2024000 47000 54000 6323000 6517000 2878000 2985000 10711000 11580000 1825000 1631000 836000 879000 2661000 2510000 5843000 6039000 8504000 8549000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 200000000 200000000 8650950 8650950 8650753 8650753 1000 1000 192598000 192593000 -190392000 -189563000 2207000 3031000 10711000 11580000 500000 0 500000 0 0 1423000 1336000 3116000 1336000 4539000 -836000 -4539000 4000 17000 3000 11000 0 104000 7000 132000 -829000 -4407000 0 0 -829000 -4407000 -0.10 -0.10 -0.70 -0.70 8650878 8650878 6288952 6288952 8650753 1000 192593000 -189563000 3031000 5000 5000 197 -829000 -829000 8650950 1000 192598000 -190392000 2207000 4965901 0 187571000 -172649000 14922000 308000 308000 800000 800000 5561 1000 -2000 -1000 3400000 4597000 4597000 -4407000 -4407000 8371462 1000 191674000 -177056000 14619000 -829000 -4407000 7000 251000 5000 308000 194000 180000 0 105000 -218000 -157000 0 -180000 194000 91000 -43000 199000 -196000 -172000 -450000 -3318000 0 106000 0 106000 0 5440000 0 843000 0 2000 0 4595000 -450000 1383000 2016000 9777000 1566000 11160000 0 800000 366000 816000 1200000 1200000 1566000 2016000 Description of Business, Basis of Presentation and Going Concern<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. While the foregoing efforts are continuing with respect to the Company’s historical assets, the Company does not expect they will generate significant value for stockholders. Therefore, the Company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. The Company is exploring transactions in industries unrelated to its historical operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout these unaudited condensed consolidated financial statements, the terms the “Company,” and “Exicure” refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company. Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023, and for the three months ended March 31, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated balance sheet as of March 31, 2024, the interim condensed consolidated statements of operations for the three months ended March 31, 2024 and 2023, the interim condensed consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2024 and 2023, and the interim condensed consolidated statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of March 31, 2024, the results of its operations for the three months ended March 31, 2024 and 2023, and the results of its cash flows for the three months ended March 31, 2024 and 2023. The financial data and other information disclosed in these notes related to the three months ended March 31, 2024 and 2023 are unaudited. The results for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the year ending December 31, 2024, or any other interim periods, or any future year or period. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on June 6, 2024. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the financial statements are issued. As of March 31, 2024, the Company expects to incur significant expenses and negative cash flows for the foreseeable future. As of March 31, 2024, the Company’s cash and cash equivalents were $366. Management believes that, given the Company’s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. Substantial additional financing will be needed by the Company to fund its operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the Company’s existing cash and cash equivalents are insufficient to continue to fund its operating expenses and additional funding is needed in the very near term. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend the Company’s operating runway is limited. As a result, substantial additional financing will be needed by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div>The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and December 31, 2023, and for the three months ended March 31, 2024 and 2023, have been presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div> 366000 Significant Accounting Policies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company’s Annual Report on Form 10-K (the “Annual Report”) for the year ended December 31, 2023 filed with the SEC on June 6, 2024. Since the date of those audited consolidated financial statements, there have been no material changes to the Company’s significant accounting policies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. Supplemental Balance Sheet Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:72.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid franchise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other noncurrent assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:72.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Other noncurrent assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:72.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $7 and $251 for the three months ended March 31, 2024 and 2023, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:72.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:72.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid franchise tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 480000 508000 160000 259000 250000 235000 70000 95000 63000 72000 73000 24000 1096000 1193000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other noncurrent assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:72.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Other noncurrent assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1200000 1200000 1678000 1785000 2878000 2985000 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:72.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 246000 246000 3000 3000 30000 30000 279000 279000 232000 225000 47000 54000 7000 251000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:72.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 650000 626000 43000 71000 143000 182000 836000 879000 Leases<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s lease arrangements at March 31, 2024 consist of (i) a lease for office space at its headquarters in Chicago, Illinois that commenced in July 2020 (the “Chicago Lease”) and (ii) a lease for office equipment (the “Office Equipment Lease”). The Chicago Lease and the Office Equipment Lease are classified as operating leases.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chicago Lease</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately thirty thousand square feet of office space in Chicago, Illinois. The original term (the “Original Term”) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the “Commencement Date”), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the “Extension Periods”) at the then prevailing effective market rental rate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes were subject to certain abatements. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company’s unaudited condensed consolidated statement of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.314%"><tr><td style="width:1.0%"></td><td style="width:57.551%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments for operating leases $0 and $646 during the three months ended March 31, 2024 and 2023, respectively. Amounts owed are included in accounts payable as of March 31, 2024. On June 11, 2024, the Company received a formal notice from its landlord indicating the landlord will draw on the restricted cash account designated for the lease as a result of past due rent for December 2023 through June 2024. This draw is within the terms and conditions of the lease and the related restricted cash account. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease of Office Space</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a sublease agreement with Cyclopure, Inc. (the “Subtenant”) to sublease approximately 57% of its office space pursuant to that certain sublease agreement (the “Sublease Agreement”), dated as of May 4, 2023. The term of the Sublease Agreement began on May 15, 2023 and ends on June 30, 2030, the expiration date of the Chicago Lease. The first three months under the Sublease Agreement are rent free. Beginning August 15, 2023, the Company began charging the Subtenant for 57% of the base rent under the Chicago Lease, and the subtenant is responsible for its pro rata share of operating expenses and taxes payable. In 2024, the Company does not receive payment from the Subtenant as the Subtenant pays the Company’s landlord directly. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes sublease receipts in the Company’s condensed consolidated statement of operations:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.564%"><tr><td style="width:1.0%"></td><td style="width:54.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease amounts paid to landlord</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30000 P10Y 2 P5Y 1113000 0.03 12761000 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company’s unaudited condensed consolidated statement of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.314%"><tr><td style="width:1.0%"></td><td style="width:57.551%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes sublease receipts in the Company’s condensed consolidated statement of operations:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.564%"><tr><td style="width:1.0%"></td><td style="width:54.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease amounts paid to landlord</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 143000 326000 120000 332000 11000 0 274000 658000 0 646000 0.57 P3M 0.57 173000 0 173000 0 Investment in Convertible Notes Receivable<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company entered into two subscription agreements to purchase non-guaranteed private placement convertible notes receivable (the “Notes Receivable”) for a subscription amount of $1 million each. The Notes Receivable mature in May 2026 and the yield to maturity is 4.5% per annum. The Company has the option to request that the issuer redeem part or the entire principal amount of the Notes Receivable on the first anniversary after the issue date and every three months thereafter before the maturity date. The conversion ratio will be one hundred percent (100%) of the Notes Receivable’s face value. The Company also has the ability to convert the debt into shares based on the number of shares computed by dividing the face value of each security by a calculated conversion price, which is subject to adjustment provisions, determined at the time of issuance. The securities may be converted from May 3, 2024, the first anniversary of the issue date of the first agreement, to April 15, 2026, one month prior to the maturity date to the second agreement. In March 2024, the Company notified the issuer of the Notes Receivable that it was exercising its redemption right with respect to the entire principal amount of the Notes Receivable after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of $2.090 million (representing the principal amount plus 4.5% per annum yield to the redemption date). The issuer has taken the position that the Notes Receivable are not redeemable until August 3, 2024 and August 16, 2024. </span></div>The Company’s debt securities are classified as AFS pursuant to Accounting Standards Codification (“ASC”) 320 - Investments - Debt Securities. AFS securities are recorded at fair value. As of March 31, 2024 and December 31, 2023, management does not believe these AFS investments are recoverable and recorded them at a fair value of $0. 2 1000000 1000000 0.045 P3M 1 2090000.00 0.045 0 0 Stockholders’ Equity<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, the Company had authorized 200,000,000 shares of common stock, par value $0.0001. As of March 31, 2024 and December 31, 2023, the Company had 8,650,950 shares and 8,650,753 shares issued and outstanding, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of the Company’s common stock are entitled to one vote per share on all matters to be voted upon by the Company’s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company’s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board of Directors (the “Board”) out of funds legally available for that purpose. In the event of the Company’s liquidation, dissolution or winding up, the holders of shares of the Company’s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company’s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company’s common stock. The outstanding shares of the Company’s common stock are fully paid and non-assessable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">September 2022 PIPE (Private Investment in Public Equity)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with CBI USA, Inc. (“CBI USA”), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of $1.60 per share. The private placement closed on February 24, 2023 (the “Closing Date”). The Company received gross proceeds of $5,440 from the September 2022 PIPE (or net proceeds of $4,597 after transaction expenses). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. (“DGP”). On June 23, 2023, DGP exercised its the option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on June 30, 2024.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any “group” of which it or they are a member with the right to designate directors to the Company’s board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on June 30, 2024.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 2022 Registration Rights Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement with CBI USA (the “Registration Rights Agreement’). CBI USA assigned its rights under the Registration Rights Agreement to DGP when DGP acquired the 3,400,000 shares of Common Stock initially sold to CBI USA. Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the shares of Common Stock sold pursuant to the Securities Purchase Agreement, to use reasonable best efforts to cause such registration statement to become effective as promptly as practicable, and to keep such registration statement continuously effective until the earlier of (i) the date the shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction, or (ii) the date that is two (2) years following the Closing Date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the registration statement was not filed within 90 days following the Closing Date, subject to certain limited exceptions, the Company agreed to make payments as liquidated damages in an amount equal to 0.5% of the aggregate amount invested in the shares of Common Stock pursuant to the Securities Purchase Agreement per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. We have paid $27 to CBI USA and accrued $191 to DGP pursuant to this provision.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered Direct Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the Company completed a securities purchase agreement (the “Purchase Agreement”) with certain institutional purchasers (the “Purchasers”) entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at-the-market consistent with the rules of Nasdaq (the “Registered Direct Offering”), (i) an aggregate of 433,553 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 718,981 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 576,261 shares of Common Stock (the “Warrants”). The combined purchase price of each share of Common Stock and accompanying Warrant is $9.9780 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is $9.9480 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.03). The per share exercise price for the Warrants is $8.1031, the closing bid price of the Company’s Common Stock on December 13, 2021 (and as adjusted for the reverse stock split referenced in Note 1). The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders’ equity within additional paid-in-capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were $11,478 and net proceeds after deducting the placement agent’s fees and other offering expenses paid or payable by the Company were $10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the “Registration Statement”).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant is exercisable for one share of Common Stock at an exercise price of $8.1031 per share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.030 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder’s option upon issuance, 9.99%) of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares of Common Stock to the Warrant holder.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase 576,261 shares of common stock at a price of $8.1031 per share were acquired in the December 2021 registered-direct offering transaction. The warrants were classified as equity. As a result of the closing of the September 2022 PIPE, a warrant holder elected to exercise their option within 30 days of the closing of the September 2022 PIPE (February 24, 2023) to receive a cash payout for the outstanding warrants in the amount of the Black-Scholes value of each warrant as prescribed in the warrant agreement. The Company paid $800 to this warrant holder on June 23, 2023 and 526,151 were settled as a result. As of March 31, 2024, warrants to purchase 50,110 shares of common stock at a price of $8.1031 per share that were acquired in the December 2021 registered-direct offering transaction remain outstanding.</span></div> 10000000 10000000 0.0001 0.0001 0 0 0 0 200000000 200000000 0.0001 0.0001 8650950 8650950 8650753 8650753 1 3400000 1.60 5440000 4597000 3400000 0.10 340000 0.45 3400000 P90D 0.005 P30D 27000 191000 433553 0.0001 718981 576261 9.9780 9.9480 0.03 8.1031 P5Y 11478000 10226000 1 8.1031 P5Y 0.0499 0.0999 1 0.030 0.0499 0.0999 576261 8.1031 800000 526151 50110 8.1031 Equity-Based Compensation<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2017, the Company’s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 194,750 shares of Exicure common stock, which includes 72,330 shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 122,793 that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the “2015 Plan”) and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 153,333 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the “Compensation Committee”). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2023, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 153,333 awards.         </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 455,765.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted under the 2017 Plan are contingent on the participants’ continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Employee Stock Purchase Plan (the “ESPP”) was adopted by the Board in September 2017 and approved by the Company’s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 250 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee’s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 10,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2023, the number of shares of common stock available for issuance under the ESPP increased by 10,000 shares. As of March 31, 2024, there were 61,971 shares available for issuance under the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.314%"><tr><td style="width:1.0%"></td><td style="width:57.551%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized equity-based compensation expense at March 31, 2024 was $27, which is expected to be amortized over a weighted-average period of 1.6 years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The model also requires the input of highly subjective assumptions. No options were granted during the three months ended March 31, 2024. The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the three months ended March 31, 2023:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.762%"><tr><td style="width:1.0%"></td><td style="width:71.342%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 to 5.8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83% to 3.83%; weighted avg. 3.83%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0% to 101.0%; weighted avg. 101.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term is based upon the “simplified method” as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the “simplified method” until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. For stock options granted after December 31, 2021, the expected volatility is based on the volatility of shares of the Company. For stock options granted prior to January 1, 2022, the expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2023 are summarized in the table below. No options were granted during the three months ended March 31, 2024.</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:53.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.58; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.58</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.58;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.58</span></div></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of common stock options granted in the three months ended March 31, 2023 was $1.26 per common stock option.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:37.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows: </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"></td><td style="width:58.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.674%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is based on the Company’s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company’s common stock. Restricted stock units generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.</span></div> 194750 72330 122793 153333 0.05 153333 455765 0.25 P48M P48M P36M P12M P10Y 0.15 250 25000 0.85 10000 0.003 10000 61971 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.314%"><tr><td style="width:1.0%"></td><td style="width:57.551%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 154000 5000 154000 5000 308000 27000 P1Y7M6D 0 The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the three months ended March 31, 2023:<div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.762%"><tr><td style="width:1.0%"></td><td style="width:71.342%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 to 5.8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83% to 3.83%; weighted avg. 3.83%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0% to 101.0%; weighted avg. 101.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the three months ended March 31, 2023 are summarized in the table below. No options were granted during the three months ended March 31, 2024.</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:53.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three months ended March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.58; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.58</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.58;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.58</span></div></td></tr></table></div> P5Y9M18D P5Y9M18D 0.0383 0.0383 0.0383 1.010 1.010 1.010 0.05 0 0 1.58 1.58 1.58 1.58 1.26 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:37.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12115 4.28 P5Y4M24D 0 0 0 0 0 416 5.51 11699 5.51 P5Y1M6D 0 11699 5.51 P5Y1M6D 0 11699 5.51 P5Y1M6D 0 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows: </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"></td><td style="width:58.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.674%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3043 10.41 0 0 296 18.47 417 3.45 2330 13.03 1 P4Y Income TaxesThe Company incurred a pretax loss in each of the three months ended March 31, 2024 and 2023, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended. The effective tax rate is 0% in each of the three months ended March 31, 2024 and 2023 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets. 0 0 0 0 Loss Per Common Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the three months ended March 31, 2024 and 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.865%"><tr><td style="width:1.0%"></td><td style="width:54.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(829)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,650,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:64.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three months ended March 31, 2024 and 2023:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.865%"><tr><td style="width:1.0%"></td><td style="width:54.131%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(829)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,650,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -829000 -4407000 8650878 8650878 6288952 6288952 -0.10 -0.10 -0.70 -0.70 <div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:64.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11699 203406 2330 8784 0 97643 50110 576261 Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of March 31, 2024 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"></td><td style="width:42.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in convertible notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of December 31, 2023 are as follows: </span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.147%"><tr><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in convertible notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company uses the market approach and Level 3 inputs to value its liabilities. There were no liabilities measured at fair value on a recurring basis as of as of December 31, 2023 nor March 31, 2024. </span></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, 2, or 3, during the three months ended March 31, 2024, and 2023. Both observable and unobservable in puts were used to determine fair value of the positions that the Company classified within the Level 3 category. Unrealized gains and losses associated within the Level 3 category include changes in fair value that were attributable to both observable and unobservable inputs.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of March 31, 2024 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"></td><td style="width:42.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in convertible notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of December 31, 2023 are as follows: </span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.147%"><tr><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in convertible notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 273000 273000 0 0 0 0 0 0 273000 273000 0 0 1629000 1629000 0 0 0 0 0 0 1629000 1629000 0 0 Commitments and Contingencies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663. On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti &amp; Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. The parties filed a joint status report noting the mediation efforts taken by the parties. The report also proposes a litigation schedule going forward, which the Court adopted: plaintiff's third amended complaint is due on or before June 28, 2024, and any motion to dismiss is due on or before August 27, 2024, with response due on or before October 8, 2024 and any reply due on or before November 5, 2024. Accordingly, the status hearing set for May 22, 2024 is reset to July 23, 2024.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Dr. Giljohann and Mr. Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned Stourbridge Investments LLC v. Exicure, Inc. et al., Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints (collectively, the “Derivative Complaints”) allege that the defendants caused the Company to issue false and/or misleading statements in the proxy statement for its 2021 Annual Meeting of Stockholders regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee’s separation from the Company. The parties will proceed with paper discovery and an in-person settlement conference is scheduled for June 26, 2024.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Northwestern University License Agreements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2011, (1) AuraSense, LLC, the Company’s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC’s 2009 license agreement with Northwestern University (“NU”) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the “assigned field”); (2) in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3) in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company’s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee’s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company. In August 2015, the Company entered into a restated license agreement with NU (the “Restated License Agreement”). In February 2016, the Company obtained exclusive license as to NU’s rights in certain SNA technology it jointly owns with NU (the “Co-owned Technology License”). The Company’s license to NU’s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. The Company’s rights and obligations in the Co-owned Technology License agreement is substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as “the Northwestern University License Agreements”). As of March 31, 2024, the Company has paid to NU an aggregate of $11,567 in consideration of each of the obligations described above. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2023, the company received a notice letter (the “Letter”) from counsel for NU alleging the Company breached the Northwestern University License Agreements. The Letter alleges that a lack of development required under the Northwestern University License Agreements is a breach. The Northwestern University License Agreements were subsequently terminated on September 10, 2023 and October 3, 2023, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the commitments associated with the Company’s lease agreements.</span></div> 11567000 Related-Party Transactions<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a Consulting Agreement, effective as of September 25, 2022, between the Company and Alta Companies LTD (“Alta”), the Company paid Alta $218 on February 27, 2023 for a consulting fee earned as a result of the September 2022 PIPE closing. Paul Kang, a director of the Company since February 2023 and the CEO of the Company since August 2023, is the President of Alta.</span></div> 218000 License Agreement<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis with a private clinical stage biopharmaceutical company. Under the terms of the agreement, this biopharmaceutical company will receive an exclusive license in the field of hepatitis to all of the Company’s relevant patents. An initial payment of $500 was paid to the Company after the execution of this agreement. This payment was recognized as revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will also be entitled to modest royalties on future net sales on all licensed technology during the term of the licensed patents. The Company will be responsible for, and make all decisions concerning, the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preparation, filing, prosecution, and maintenance for each patent and patent application included within the licensed patents.</span></div> 500000 Subsequent Events<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2024, the Company executed a promissory note (“Note”) and subsequently received a loan in the amount of $300 from an individual investor. All principal and accrued interest will be due and payable on the earlier of (i) the 1st anniversary of the date of this Note or (ii) upon an event of default, at that time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this Note at 6.0% and is payable at maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2024, the Company executed another promissory note (“DGP Note”) and subsequently received a loan in the amount of $700 from DGP, a related party. All principal and accrued interest will be due and payable on the earlier of (i) the ten-month anniversary of the date of this DGP Note or (ii) upon an event of default, at that time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this DGP Note at 6.0% and is payable at maturity.</span></div> 300000 0.060 700000 P10M 0.060 false false false false